Valve & Structural

Tracks

Coronary

Valve & Structural

Endovascular

Atherosclerosis

Imaging

Technology & Regulatory

Nurses & Technologists

TRACKS

Coronary

Valve & Structural

Endovascular

Atherosclerosis

Imaging

Technology & Regulatory

Nurses & Technologists
Valve & Structural

LVWS and LV Remodeling Characterize Aortic Stenosis and Mitral Regurgitation: Single-Center Study

Aortic stenosis (AS) and mitral regurgitation (MR) are characterized by different left ventricular wall stress (LVWS) and left ventricular (LV) remodeling, a new study finds, which assesses the effect MitraClip (MC) and transcatheter aortic valve replacement (TAVR) have on LVWS.

Severe Aortic Wall Thrombus in TAVR Patients Linked to Thromboembolic Complications, Including Stroke

The presence of severe aortic wall thrombus (AWT) on pre-procedural multidetector computed tomography (CT) is strongly associated with thromboembolic complications, including stroke and mortality, in patients undergoing transfemoral (TF) transcatheter aortic valve replacement (TAVR), an analysis of patient data reports.

Breaking News: Edwards Lifesciences to Acquire JenaValve and Endotronix

(BUSINESS WIRE) Edwards Lifesciences agreed to acquire JenaValve Technology and Endotronix on Wednesday, adding to their structural heart portfolio.

Controversial SuAVR Procedures Could Have Midterm Advantages, But Longterm Outcomes Are Unclear: State-of-the-Art Review

Sutureless aortic valves appear to have some midterm advantages versus surgical and transcatheter aortic valve replacement, including reduced surgery time, but long-term outcomes are still unclear, according to a new meta-analysis of observational evidence.

Complete Revascularization Superior in Reducing All-Cause Mortality, Meta Analysis Finds

Complete revascularization leads to significant reductions in all-cause mortality, cardiovascular mortality, myocardial infarction (MI) and major adverse cardiovascular events (MACE) compared with culprit revascularization, according to a new study.

CardioTubeMore Videos »

ACC.16 - Papillary Muscle Approximation vs. Restrictive Annuloplasty for Severe Ischemic MR

ACC16 Volumes and Outcomes for TAVR

ACC16 2-Year Outcomes of Surgical Treatment of Moderate Ischemic MR

ACC16 TAVR vs Surgery in Aortic Stenosis

ACC.16 - Incidence and Outcomes of Valve Hemodynamic Deterioration in TAVR in US Clinical Practice

In the News
More »

Patients With Under-Expanded ACURATE neo2 Valve at Greater Risk of Death, Stroke, Rehospitalization: ACURATE IDE Post-Hoc Analysis

May 21, 2025 by
Bailey G. Salimes, CRTonline.org

PARIS – A post-hoc analysis of the ACURATE IDE trial shows that under-expansion of the ACURATE neo2 valve is associated with a higher risk for death, stroke or rehospitalization.

Pooled Cohort Study Shows Higher Device Success, Lower Safety Rates in Navitor vs Evolut and ACURATE valves

May 21, 2025 by
Bailey G. Salimes, CRTonline.org

PARIS – Higher device success but lower early safety rates are more prominent in the use of the Navitor (NAV) system in patients undergoing transcatheter aortic valve implantation (TAVI) compared with the use of the Evolut PRO/PRO+ (PRO) and ACURATE neo2 (NEO2) valves, a new pooled analysis shows.

Wide-Scale CEP Meta-Analysis Shows No Reduced Post-TAVI Overall Stroke Risk

May 21, 2025 by
Natalie Morrison, CRTonline.org

A new meta-analysis of more than 10,500 patients in the two largest randomized trials to-date testing the SENTINEL cerebral embolic protection (CEP) device as a way to protect against peri-procedural stroke during transcatheter aortic valve implantation (TAVI) confirmed there is no associated risk reduction overall for stroke.

Myval THV Still Non-Inferior to Sapien and Evolut at 1-Year in LANDMARK Study

May 21, 2025 by
Natalie Morrison, CRTonline.org

The Myval transcatheter heart valve (THV) was non inferior versus contemporary THVs in patients with symptomatic severe native aortic stenosis at 1-year post-procedure, according to the latest LANDMARK trial follow-up.

Redo-TAVR More Feasible Choice for Bicuspid vs Tricuspid Aortic Valves: Simulation Study

May 13, 2025 by
Will Chu, CRTonline.org

Researchers reveal that patients with bicuspid aortic valves may have a higher chance of successful repeat transcatheter aortic valve replacement (redo-TAVR) compared to those with tricuspid valves.

Study Shows Ultrasound Imaging May Reduce Unnecessary Coronary Stenting in Patients Undergoing TAVR

May 13, 2025 by
Will Chu, CRTonline.org

New insights from a multicenter European study demonstrate that intravascular ultrasound (IVUS) can safely and effectively guide decisions to avoid unnecessary coronary stenting during transcatheter aortic valve replacement (TAVR).

Navitor TAV at Low Implant Depths is ‘More Favorable’ than Other SEVs and Higher Depths: Real-World Simulation

May 01, 2025 by
Natalie Morrison, CRTonline.org

The Navitor transcatheter aortic valve (TAV) implanted at low implant depths led to more favorable redo procedures than higher depths and other self-expanding valves (SEV), according to a new simulation.

Catheter Ablation Significantly Reduces Functional MR and TR in AF with LVSD: 1-Year Multi-Study Analysis

Apr 30, 2025 by
Natalie Morrison, CRTonline.org

The degree of functional mitral regurgitation (FMR) in patients with atrial fibrillation (AF) and left ventricular systolic dysfunction (LVSD) does not impact the success of catheter ablation (CA), a multi-study analysis shows, but CA does significantly reduce both FMR and functional tricuspid regurgitation (FTR) at 1 year.

High Pacemaker Rates After TAVR Treatment Highlighted in New Review

Apr 23, 2025 by
Will Chu, CRTonline.org

A review highlights the ongoing challenge of conduction disturbances (CDs) following transcatheter aortic valve replacement (TAVR), revealing that the incidence remains “in the double-digit range,” with permanent pacemaker implantation (PPI) rates exceeding 10%.

Self-Sealing Type A Aortic Dissection During TAVR: Case Report Highlight

Apr 21, 2025 by
Nathan Gray, CRTonline.org

A new case report demonstrates the rare instance of a type A aortic dissection spontaneously sealing after transcatheter heart valve deployment, allowing for successful conservative management in a high-risk patient.

TAVR Achieves Comparable Echocardiographic Outcomes to Surgery for Low-Risk AS Patients: 5-Year PARTNER 3 Data

Apr 18, 2025 by
Nathan Gray, CRTonline.org

Compared to surgery, transcatheter aortic valve replacement (TAVR) achieves similar valve hemodynamic performance and durability in low-risk patients with severe aortic stenosis (AS), according to new 5-year echocardiographic data from the PARTNER 3 trial.

Machine Learning Reveals Unique Clusters in Patients With Aortic Regurgitation

Apr 16, 2025 by
Bailey G. Salimes, CRTonline.org

New research shows machine learning is useful in enhancing risk stratification for patients with aortic regurgitation (AR), including the description of 4 distinct phenoclusters within this patient population.

New Potential Alternative to Plasma for Cardiac Surgery Patients Requiring Coagulation Factor Replacement

Apr 16, 2025 by
Bailey G. Salimes, CRTonline.org

Patients who receive 4-factor prothrombin complex concentrate (PCC) for bleeding complications during cardiac surgery have superior hemostatic and safety outcomes compared with patients who receive frozen plasma, a new analysis shows.

Subclinical Liver Cirrhosis Associated With Poor TTVR Prognosis: Real-World Study

Apr 15, 2025 by
Natalie Morrison, CRTonline.org

Subclinical liver cirrhosis associated with tricuspid regurgitation (TR) is linked with poor prognosis in tricuspid valve replacement (TTVR patients), despite TR abolishment, according to a new single-center, real-world analysis of Canadian patients.

Refined Patient Selection Enhances Success in Transcatheter Tricuspid Annuloplasty

Apr 14, 2025 by
Will Chu, CRTonline.org

Optimizing patient selection and procedural strategies can significantly improve outcomes in transcatheter tricuspid valve annuloplasty (TTVA), according to new research published in JACC: Cardiovascular Interventions.

Study Uses 4D-CTA Imaging to Link CIED Leads to Progressive Tricuspid Valve Damage

Apr 14, 2025 by
Will Chu, CRTonline.org

New study findings reveal how leads from pacemakers and other cardiac implantable electronic devices (CIEDs) can contribute to or worsen tricuspid regurgitation (TR) by interfering with valve anatomy.

TTVR With LuX-Valve Reduces TR at 1-Year in TRAVEL Study

Apr 14, 2025 by
Natalie Morrison, CRTonline.org

Transcatheter tricuspid valve replacement (TTVR) with the LuX-Valve system led to a sustains reduction in tricuspid regurgitation (TR) over 1 year in the TRAVEL study.

Review Cautions Early Aortic Valve Replacement for Low-Risk Aortic Stenosis

Apr 08, 2025 by
Will Chu, CRTonline.org

Newly published findings are questioning physicians’ enthusiasm for early aortic valve replacement (AVR) in patients with asymptomatic severe aortic stenosis (AS).

EARLY TAVR Sub-Analysis Shows Benefits of Early TAVR Regardless of Baseline Biomarker Levels

Mar 31, 2025 by
Bailey G. Salimes, CRTonline.org

Patients with severe, asymptomatic aortic stenosis (AS) benefit from early transcatheter aortic valve replacement (TAVR) regardless of baseline cardiac biomarker levels, but these benefits are more pronounced in patients with lower levels of biomarkers, a sub-analysis of the EARLY TAVR trial shows.

Patients With Severe, Asymptomatic AS, AVS and Delayed AVR Show Worse Clinical Outcomes Than Early TAVR Patients: EARLY TAVR Sub-Analysis

Mar 31, 2025 by
Bailey G. Salimes, CRTonline.org

Acute valve syndrome (AVS) plus delayed aortic valve replacement (AVR) is associated with a higher risk of death, stroke or heart failure hospitalization (HFH) in patients with severe aortic stenosis (AS) within 2 years after the procedure, compared with early transcatheter aortic valve replacement (TAVR), a sub-analysis of the EARLY-TAVR trial shows.

Provider Email Notifications Improve Treatment Strategies, Equity Gaps in Patients With Severe AS: DETECT AS Trial

Mar 31, 2025 by
Bailey G. Salimes, CRTonline.org

Electronic provider notifications (EPN) have a significant impact on rates of aortic valve replacement (AVR) in patients with severe, symptomatic aortic stenosis (AS), including improved survival times and narrowing disparity gaps, data from the DETECT AS trial show.

Tricuspid TEER Continues to Improve QoL, Severity of TR, HF Hospitalization Rates: 2-Year TRILUMINATE Study Update

Mar 30, 2025 by
Bailey G. Salimes, CRTonline.org

At 2-years, tricuspid transcatheter edge-to-edge repair (TEER) is safe and significantly reduces the severity of tricuspid regurgitation (TR) and rates of heart failure hospitalization (HFH) compared to medical therapy alone in patients with severe, symptomatic tricuspid regurgitation.

Evolut Low Risk 5-Year Analysis Shows Similar Outcomes in Patients With AS Undergoing TAVR vs SAVR

Mar 30, 2025 by
Bailey G. Salimes, CRTonline.org

Patients who are treated with either transcatheter aortic valve replacement (TAVR) with Evolut or surgical AVR (SAVR) for aortic stenosis (AS) have comparable rates of all-cause death or disabling stroke at 5-years, results from the Evolut Low Risk trial show.

JenaValve Trilogy System Exceeds Expectations for 1-Year Safety Endpoint: ALIGN-AR

Mar 30, 2025 by
Bailey G. Salimes, CRTonline.org

Results from the ALIGN-AR trial, investigating patients with aortic regurgitation (AR) who undergo transcatheter aortic valve replacement (TAVR) with the JenaValve Trilogy system, show that patients have an overall mortality rate of 8.1% at 1-year follow-up, compared with the prespecified goal of 25% to demonstrate noninferiority.

CEP Not Protective Against Stroke in Patients Undergoing TAVI: British Heart Foundation Study

Mar 30, 2025 by
Bailey G. Salimes, CRTonline.org

The incidence of stroke within 3 days is not decreased by routine use of cerebral embolic protection (CEP) in patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve implantation (TAVI).

Dapagliflozin Safe in Older Patients With AS, HF Undergoing TAVI

Mar 29, 2025 by
Bailey G. Salimes, CRTonline.org

Dapagliflozin significantly lowers the rate of death from any cause or worsening heart failure (HF) compared with standard care alone in elderly patients with aortic stenosis (AS) undergoing transcatheter aortic valve implantation (TAVI), data from a newly published trial show.

Novel Balloon-Expandable Valve for Aortic Regurgitation Shows Promising Early Results

Mar 24, 2025 by
Nathan Gray, CRTonline.org

The first transfemoral balloon-expandable transcatheter heart valve for pure native aortic regurgitation (PNAR) shows a low incidence of adverse safety events and good clinical outcomes at 30 days, with notably low rates of paravalvular leak and permanent pacemaker implantation (PPI), early trial data suggests.

Study Shows Decrease in Use of Embolic Protection Devices With TAVR

Mar 20, 2025 by
Bailey G. Salimes, CRTonline.org

A new research letter shows a decrease in the use of embolic protection devices with transcatheter aortic valve replacement (TAVR) post-PROTECTED TAVR trial results.

TELLTALE Device Prevents Coronary Obstruction in High-Risk TAVR Patients

Mar 13, 2025 by
Bailey G. Salimes, CRTonline.org

WASHINGTON, DC - Transcatheter aortic valve replacement (TAVR) with the use of the TELLTALE Leaflet Modification System prevents coronary obstruction in patients who have native aortic stenosis (AS) or bioprosthetic valve failure with high-risk anatomy, a new study shows.

Positive PATCH Trial Results Send PerQSeal Vascular Patch Heading for FDA Submission

Mar 11, 2025 by
Natalie Morrison, CRTonline.org

The PerQSeal resorbable vascular patch showed low rates of major vascular complications and rapid hemostasis rates when used for the closure of large bore arteriotomies in the US pivotal PATCH trial.

Supra-Annular, Intra-Annular TAVR-in-TAVR Show Comparable Procedural Success: Registry Data

Mar 10, 2025 by
Nathan Gray, CRTonline.org

The use of supra-annular valves (SAV) and intra-annular valves (IAV) as a second prosthesis in transcatheter aortic valve replacement (TAVR)-in-TAVR procedures shows comparable procedural success and early outcomes, an analysis of international registry data suggests.

Balloon-Expandable Valves Outperform Self-Expanding Valves in TAVR Outcomes, Study Concludes

Mar 10, 2025 by
Will Chu, CRTonline.org

Results of a pooled analysis comparing outcomes of transcatheter aortic valve replacement (TAVR) suggest lower odds of device success and early safety with self-expanding valves (SEV) versus balloon-expandable valves (BEV).

TriClip Upholds 1-Year Procedural Safety in TR: TRILUMINATE Pivotal Early Results

Mar 10, 2025 by
Natalie Morrison, CRTonline.org

The TriClip device demonstrates procedural safety in severe, symptomatic tricuspid regurgitation patients (TR) at 1 year, and is safe in patients with cardiac implantable electronic device (CIED) leads, results from the TRILUMINATE Pivotal study show.

Patient Prosthesis Mismatch Not Associated With Lowered Quality of Life at 1-Year Post-TAVI

Mar 10, 2025 by
Nathan Gray, CRTonline.org

Severe patient prosthesis mismatch (PPM) is not associated with a lower quality of life (QOL) at 1 year, compared with no PPM, in patients who undergo transcatheter aortic valve implantation (TAVI), a new analysis of patient data shows.

RCT Data Suggests Nickel Hypersensitivity Associated With Device Syndrome After PFO Closure

Mar 09, 2025 by
Nathan Gray, CRTonline.org

Patients with documented nickel hypersensitivity are more than 10 times more likely to develop device syndrome after undergoing patent foramen ovale (PFO) closure than those without, according to the first prospective, double-blinded, randomized trial to evaluate the impact of nickel hypersensitivity on clinical outcomes.

Moderate AS Associated With Higher Mortality Rates vs Mild AS, Study Suggests

Mar 09, 2025 by
Will Chu, CRTonline.org

New study findings provide critical insights into the natural history of mild to moderate aortic stenosis (AS) and identify potential risk factors for disease progression.

BVD Linked to Worse Clinical Outcomes in Retrospective Study

Mar 09, 2025 by
Natalie Morrison, CRTonline.org

Bioprosthetic valve dysfunction (BVD) is associated with a significant increased risk of poor clinical outcomes regardless of aortic valve replacement therapy and annular size, according to a new retrospective analysis of clinical and observational trial data.

Unilateral Dry-Closure Technique Provides Safe, Effective Access in High-Risk TAx-TAVI Patients

Mar 09, 2025 by
Nathan Gray, CRTonline.org

A unilateral, suture-based dry-closure technique facilitates safe and effective access management in high-risk patients selected for percutaneous Trans-axillary transcatheter aortic valve implantation (TAx-TAVI) procedures, new data suggests.

TELLTALE Device Prevents Coronary Obstruction in High-Risk TAVR Patients

Mar 09, 2025 by
Bailey G. Salimes, CRTonline.org

WASHINGTON, DC - Transcatheter aortic valve replacement (TAVR) with the use of the TELLTALE Leaflet Modification System prevents coronary obstruction in patients who have native aortic stenosis (AS) or bioprosthetic valve failure with high-risk anatomy, a new study shows.

Similar 1-Year Clinical Outcomes in ACURATE neo2, SAPIEN, Evolut TAVI: SWEDEHEART Emulates ACURATE IDE

Mar 09, 2025 by
Bailey G. Salimes, CRTonline.org

Mortality, heart failure hospitalization and stroke are similar between-groups when comparing the ACURATE neo2 and SAPIEN/Evolut transcatheter aortic valve implantation (TAVI), observational data from Swedish studies show.

TAVR for Failing Bioprosthetic Surgical Valves Shows Favorable Outcomes at 5-Years

Mar 09, 2025 by
Will Chu, CRTonline.org

Data from the PARTNER 3 Aortic Valve-in-Valve (AViV) registry demonstrates the long-term safety and effectiveness of transcatheter aortic valve replacement (TAVR) for failing bioprosthetic surgical valves in low- and intermediate-risk patients.

2-Year SMART Results Show Similar Clinical Outcomes in SEV vs BEV in Patients With Severe AS and Small Aortic Annuli

Mar 09, 2025 by
Natalie Morrison, CRTonline.org

Supra-annular self-expanding valves (SEV) demonstrate significantly lower dysfunction rates than balloon-expandable valves (BEV) in severe aortic stenosis (AS) patients in the SMART trial at 2-years, with similar clinical outcomes between the two groups.

Novel Self-Centering Crossing Catheter Successful, Safe During TAVR for Severe AS

Feb 19, 2025 by
Bailey G. Salimes, CRTonline.org

A novel Self-Centering Guide Catheter (SCGC) used during transcatheter aortic valve replacement (TAVR) in patients with severe aortic stenosis (AS) shows no safety concerns and successfully operates during TAVR, a first-in-human study shows.

Transapical TMVR: A Promising Alternative for Failed M-TEER Procedures

Feb 10, 2025 by
Will Chu, CRTonline.org

Study findings published in Feb 10 edition of JACC: Cardiovascular Interventions detail the effectiveness of transapical transcatheter mitral valve replacement (TMVR) following failed transcatheter edge-to-edge repair (M-TEER).

TR Stage May Influence 1-Year T-TEER Survival Outcomes: Registry Analysis

Feb 10, 2025 by
Nathan Gray, CRTonline.org

Tricuspid regurgitation (TR) disease stage may influence survival outcomes following tricuspid transcatheter edge-to-edge repair (T-TEER), according to a new analysis of 1-year follow-up data that suggests individuals with intermediate TR may receive the most substantial treatment benefits.

Lower All-Cause Mortality in Mechanical vs Bioprosthetic Aortic Valve Replacement: Real-World Analysis

Feb 04, 2025 by
Bailey G. Salimes, CRTonline.org

Mechanical surgical aortic valve replacement (AVR) is independently associated with significant survival benefits compared with bioprosthetic AVR in patients aged 60 years and younger, a real-world analysis shows.

Despite Recent Advances in LAAO, Questions Remain Over Patient, Device Selection: State-of-the-Art Review

Jan 14, 2025 by
Nathan Gray, CRTonline.org

While multiple advancements in left atrial appendage occlusion (LAAO) devices have emerged for stroke prevention and arrhythmia therapy, several unanswered questions remain, specifically regarding the patient and device selection and the management of complications, according to a new review.

Non-Trial SAVR Patients Have Comparable Mortality, Fewer Strokes Than Trial Patients From PARTNER 3 and Evolut Low Risk: Cross-Sectional Study

Jan 06, 2025 by
Bailey G. Salimes, CRTonline.org

Low-risk, trial-like patients undergoing surgical aortic valve replacement (SAVR) during the trial enrollment period have similar 30-day rates of mortality, but lower rates of stroke, compared with patients in the SAVR arm of the PARTNER 3 and Evolut Low Risk trials, a cross-sectional analysis shows.

Redo TAVR With SAPIEN 3 Associated With Downsizing, Under-Expansion “Complexities”: Patient Analysis

Dec 23, 2024 by
Nathan Gray, CRTonline.org

Redo transcatheter aortic valve replacement (TAVR) with the SAPIEN 3 (S3) valve presents challenges, according to a new analysis of patient data that also shows downsizing is frequent, and under-expansion may lead to suboptimal hemodynamics.

Study Suggests Radial Access Superior to Femoral Route for Secondary Use in TAVR Procedures

Dec 23, 2024 by
Will Chu, CRTonline.org

New study findings challenge established practices in transcatheter aortic valve replacement (TAVR), as researchers demonstrate that transradial secondary access (TR-SA) significantly reduces complications compared to traditional transfemoral secondary access (TF-SA).

Potential Risk Factors for Progressive Ascending Aorta Dilation in BAV Patients Undergoing TAVR Identified: Exploratory Analysis

Dec 16, 2024 by
Natalie Morrison, CRTonline.org

A subset of bicuspid aortic stenosis patients undergoing transcatheter aortic valve replacement may be at increased risk for progressive ascending aorta dilation, according to a new exploratory analysis of 61 patients.

Revolutionary Study Maps Navitor Transcatheter Aortic Valve Geometry Using CT Imaging

Dec 09, 2024 by
Will Chu, CRTonline.org

In the first study of its kind, scientists have conducted a computed tomography (CT) analysis of the in vivo frame geometry of the Navitor intra-annular self-expanding valve (SEV).

Study Further Clarifies Distinction Between Fibrotic and Calcific Aortic Stenosis in TAVR Patients

Nov 25, 2024 by
Will Chu, CRTonline.org

Research published in JACC: Cardiovascular Interventions identifies the significant differences between fibrotic and calcific forms of aortic stenosis (AS), as researchers reveal further insights into patient characteristics and outcomes post-transcatheter aortic valve replacement (TAVR).

Better Outcomes for Dedicated Severe Native AR TAVR Devices Vs Off-Label: Meta-Analysis

Nov 25, 2024 by
Natalie Morrison, CRTonline.org

Dedicated transcatheter aortic valve replacement (TAVR) devices led to better outcomes in high-risk severe native aortic regurgitation (AR) patients than off-label alternatives, according to a new meta-analysis in more than 2,000 patients.

Study Identifies Similar One Year Outcomes for Two Transcatheter Heart Valves

Nov 25, 2024 by
Will Chu, CRTonline.org

A retrospective analysis finds no significant difference in key long-term outcomes between two advanced transcatheter heart valves in findings that provide critical insights for optimizing valve selection in transcatheter aortic valve replacement (TAVR) procedures.

Recurrent Rejection Raises Graft Rejection Risk in Pediatric Heart Transplant: PHTS Analysis

Nov 20, 2024 by
Natalie Morrison, CRTonline.org

Children who experience recurrent mixed or antibody-mediated rejection episodes of heart transplants face a higher risk of losing their graft, according to a new multi-institutional analysis.

Good Concordance Between Echo and CMR Reference, Study Reports

Nov 13, 2024 by
Nathan Gray, CRTonline.org

The quantitation of aortic regurgitation (AR) severity by transthoracic echocardiogram has good concordance against a cardiac magnetic resonance reference standard, according to a new analysis that also proposes simplified echo algorithms to evaluate significant and mild AR.

Time to Change the Guidelines? Early Echocardiographic Markers of Left Ventricular Dysfunction May Offer Survival Benefit

Nov 13, 2024 by
Nathan Gray, CRTonline.org

Patients with asymptomatic clinically significant chronic aortic regurgitation incur a survival penalty when Class I/IIa guideline recommendations are attained compared with patients who do not yet reach guideline status but do show early echocardiographic markers of early left ventricular dysfunction, new data suggests.

‘Optimal’ TR Reduction Associated With Better Functional, Clinical Outcomes After T-TEER: Registry Data

Nov 06, 2024 by
Nathan Gray, CRTonline.org

An ‘optimal’ procedural result of grade of 0/1+ regurgitation after tricuspid edge-to-edge repair (T-TEER) is associated with improved outcomes and functional status, according to an analysis of real-world patient data from the Spanish TRI-SPA registry.

TEER Has Similar Efficacy, Better Safety Post-Mitral Valve Surgery in Atrial and Ventricular Functional MR: MATTERHORN Trial

Oct 30, 2024 by
Abhishek Chaturvedi, MD, CRTonline.org

In patients with atrial functional mitral regurgitation, transcatheter edge-to-edge repair has similar efficacy and better safety profile than mitral valve surgery, according to a post-hoc analysis from the MATTERHORN trial.

M-TEER Safe, Effective Option for Degenerative MR Patients: CLASP IID Trial

Oct 30, 2024 by
Dan Haberman, MD, CRTonline.org

Two-year results from the CLASP IID Randomized Trial and Registry confirm the sustained safety and effectiveness of the PASCAL system in treating a broad population of degenerative mitral regurgitation (DMR) patients.

Under-Expansion in ACURATE Neo2 Valve Carries Higher Risk of Death, Stroke: ACURATE IDE Trial

Oct 30, 2024 by
Bailey G. Salimes, CRTonline.org

Under-expansion is a potential factor in clinical outcomes for patients with severe, symptomatic aortic stenosis receiving the ACURATE neo2 valve, results from the head-to-head ACURATE IDE trial show.

EVOQUE TTVR Boosts Severe TR Quality of Life, Despite No 1-Year Mortality or Heart Failure Improvements: TRISCEND Trial

Oct 30, 2024 by
Natalie Morrison, CRTonline.org

Transcatheter tricuspid valve replacement (TTVR) with the EVOQUE system led to substantial quality of life improvements for severe tricuspid regurgitation (TR) patients versus optimal medical therapy (OMT) alone, according to a new 1-year analysis of the TRISCEND II pivotal trial.

JenaValve Trilogy System Exhibits Favorable Survival Rate at Two Years: ALIGN-AR trial

Oct 29, 2024 by
Will Chu, CRTonline.org

The JenaValve Trilogy system provides a favorable survival rate and strong hemodynamic performance for patients at high risk for surgery with aortic regurgitation, findings from the ALIGN-AR Trial show.

Cerebral Embolic Protection During TAVR Reduced Stroke in US Cohort, Not Significant in European, Australian Cohorts: PROTECTED TAVR Trial

Oct 29, 2024 by
Lior Lupu MD, MBA, CRTonline.org

A post hoc analysis of the PROTECTED TAVR trial suggests a trend toward greater stroke reduction with cerebral embolic protection (CEP) during TAVR in the U.S. cohort, while this effect was not seen in the Europe and Australia cohort.

Combined Suture/Plug Closure Device Outperforms Suture-Only Closure Device in TAVR: ACCESS-TAVI Trial

Oct 29, 2024 by
Waiel Abusnina, MD, CRTonline.org

The ACCESS-TAVI trial revealed a significant reduction in both major and minor access site-related vascular complications with the combined suture and plug-based strategy compared to the suture-only strategy.

Researchers Halt Co-STAR Trial Due to Colchicine’s Heightened Stroke Risk Post-TAVR

Oct 29, 2024 by
Will Chu, CRTonline.org

While colchicine shows promise in mitigating inflammation-driven complications after transcatheter aortic valve replacement (TAVR), researchers in the Co-STAR trial urge a “cautious, tailored approach” to its use due to associated stroke risks.

TAVR Not Superior to AS Surveillance in Patients With Moderate AS, HFrEF on GDMT: TAVR UNLOAD Trial

Oct 28, 2024 by
Bailey G. Salimes, CRTonline.org

WASHINGTON, DC - In patients with moderate aortic stenosis (AS) and heart failure with reduced ejection fraction (HFrEF) on guideline-directed medical therapy, transcatheter aortic valve replacement (TAVR) was not superior to general AS surveillance for the composite endpoint of the TAVR UNLOAD trial.

No Benefit in Early TAVR in Asymptomatic Patients with Severe AS and Myocardial Fibrosis: EVOLVED Study

Oct 28, 2024 by
Kalyan R. Chitturi, DO, CRTonline.org

In asymptomatic severe aortic stenosis with evidence of myocardial fibrosis on cardiac MRI, early TAVR did not decrease the composite endpoint of all-cause death and aortic stenosis-related hospitalization according to the EVOLVED clinical trial.

EARLY TAVR Trial Shows Superiority of Early TAVR for Patients With Asymptomatic Severe AS

Oct 28, 2024 by
Bailey G. Salimes, CRTonline.org

WASHINGTON, DC - Early transcatheter aortic valve replacement (TAVR) is superior to clinical surveillance (CS) in patients with asymptomatic severe aortic stenosis (AS), results from the EARLY TAVR trial show.

Use of MitraClip During M-TEER to Reduce MR Shows Significant Clinical Benefits

Oct 24, 2024 by
Bailey G. Salimes, CRTonline.org

The latest generation of MitraClip systems show promising clinical benefits while reducing mitral regurgitation (MR) to mild or less after mitral transcatheter edge-to-edge repair (M-TEER), regardless of mitral valve gradient, an analysis of the EXPANDed cohort shows.

ViV-TAVR has Similar Mortality, Fewer Complications at 2-Years Compared With Redo-SAVR: Retrospective Study

Oct 16, 2024 by
Bailey G. Salimes, CRTonline.org

Valve-in-valve transcatheter aortic valve replacement (ViV-TAVR) is associated with fewer periprocedural cardiovascular complications and similar rates of all-cause mortality, compared with redo-surgical aortic valve replacement (SAVR), a new retrospective analysis shows.

Pulmonary Vein Isolation Reduces AF Burden and Improves Symptoms, QoL: SHAM-PVI Trial

Sep 02, 2024 by
Dan Haberman, MD, CRTonline.org

Pulmonary vessel isolation (PVI) with cryoballoon ablation significantly reduced atrial fibrillation (AF) burden, compared with that in the sham procedure, accompanied by clinically important in symptoms and quality of life, report investigators from the SHAM-PVI trial.

No Fasting Before Cardiac Catheterization Procedures is Safe and Patients are Satisfied, SCOFF Trial Shows

Sep 01, 2024 by
Bailey G. Salimes, CRTonline.org

Removal of fasting requirements before cardiac procedures is not only safe, but also results in more satisfied patients, say the SCOFF trial investigators.

NOTION-3 Data Reports ‘Considerable’ Benefits from PCI For TAVI Patients with CAD at 2-Year Follow-Up

Aug 31, 2024 by
Nathan Gray, CRTonline.org

Percutaneous coronary intervention (PCI) is associated with a lower risk of a major adverse events, compared with conservative treatment, in patients undergoing transcatheter aortic-valve implantation (TAVI) with coronary artery disease (CAD), reports new 2-year follow-up data from the NOTION-3 study.

TAVI Considered Superior to Surgical Aortic Valve Replacement in Women with Severe AS, RHEIA Trial Researchers Conclude

Aug 31, 2024 by
Will Chu, CRTonline.org

Newly-presented data from the RHEIA trial suggest that transcatheter aortic valve implantation (TAVI) using SAPIEN 3 or SAPIEN 3 Ultra is superior to surgical aortic valve replacement for reducing the rates of death, stroke or rehospitalization in women with severe aortic stenosis.

TAVI Patients Should Pause Oral Anticoagulants to Reduce Bleeding Risk, say POPular PAUSE TAVI Trial Authors

Aug 31, 2024 by
Natalie Morrison, CRTonline.org

Oral anticoagulants should be paused for transcatheter aortic valve implantation (TAVI), authors of the POPular PAUSE TAVI trial say, after finding patients on continued anticoagulation had bleeding but no relevant differences in thromboembolic events.

New Evidence for the Benefits of Transcatheter Edge-to-Edge Repair in Secondary Tricuspid Regurgitation: TRI.Fr Analysis

Aug 31, 2024 by
Nathan Gray, CRTonline.org

Tricuspid transcatheter edge-to-edge repair (T-TEER) significantly reduces the severity of secondary tricuspid regurgitation (TR) and improves quality of life compares to guideline-directed medical therapy (GDMT) alone, according to 12-month follow-up data from the TRI.Fr study.

TEER ‘as Effective as Surgery’ in Addressing Secondary MR: MATTERHORN Trial

Aug 31, 2024 by
Will Chu, CRTonline.org

Transcatheter edge-to-edge repair (TEER) is as effective as surgery for treating patients with secondary mitral regurgitation (MR), a new study concludes, with the technique’s better safety profile a key benefit.

Fewer Hospitalizations, Improved Health in HF Patients with Moderate-to-Severe FMR Who Receive Medical Therapy and TMVR: RESHAPE-HF2 Trial

Aug 31, 2024 by
Bailey G. Salimes, CRTonline.org

Adding transcatheter mitral-valve repair to the treatment plan of patients who have heart failure (HF) with moderate to severe functional mitral regurgitation (FMR), in addition to guideline-recommended medical therapy, leads to lower rates of first or recurrent HF hospitalization or cardiovascular death, according to results from the RESHAPE-HF2 clinical trial.

Lower MAE Risk in Post-LAAO Patients Linked to DOAC Antithrombotic Strategy, Study Suggests

Aug 26, 2024 by
Will Chu, CRTonline.org

A new analysis reveals that in patients discharged following left atrial appendage occlusion (LAAO), a direct oral anticoagulant (DOAC) antithrombotic strategy is linked to a significantly lower risk of major adverse events (MAE) when compared with anticoagulation plus aspirin.

Earlier Transcatheter Intervention Could Address Limitations in Treatment Efficacy for Heart Failure with Structural Cardiac Abnormalities – Scientific Statement

Aug 19, 2024 by
Natalie Morrison, CRTonline.org

Earlier transcatheter intervention could improve outcomes for patients with heart failure (HF) due to structural causes, for whom hospitalization and mortality rates remain high despite aggressive guideline-directed medical therapy (GDMT), according to a new scientific statement in the Journal of the American College of Cardiology.

Review Backs Use of Slow-Infusion, Low-Dose Thrombolytics as ‘Safe and Effective’ Alternative in TAVR Thrombosis Patients

Aug 19, 2024 by
Nathan Gray, CRTonline.org

Ultra-slow, low-dose infusions of thrombolysis may offer a safe and effective alternative to further interventions in the management of transcatheter aortic valve replacement (TAVR) thrombosis, particularly for patients who are resistant to standard therapies or clinically unstable, a new review suggests.

Routine Protamine Use Increases Hemostasis Success Rate: ACE-PROTAVI Trial

Aug 14, 2024 by
Will Chu, CRTonline.org

Routine use of protamine increases the rate of hemostasis success, with a shorter time to hemostasis (TTH) observed, in a study that compares the medication’s routine versus selective administration.

Brain Infarction Number, Size and Volume Linked to Stroke Type and Inferior Patient Recovery, Pooled Analysis Suggests

Aug 12, 2024 by
Will Chu, CRTonline.org

New analysis confirms that the number, size and total volume of acute brain infarctions are each associated with clinical ischemic strokes, disabling strokes and worse recovery in patients undergoing transcatheter aortic valve replacement (TAVR).

New VARC-3 Criteria Establishes Link Between Neurologic Events and Mortality Post-TAVR, Study Concludes

Aug 12, 2024 by
Will Chu, CRTonline.org

The first clinical validation of the new Valve Academic Research Consortium (VARC-3) criteria reveals a significant association between neurologic events and short-term/midterm mortality post transcatheter aortic valve replacement (TAVR).

Expert Consensus on CCT for LOAA Suggests Standardized Procedures That Will Aid New Science

Aug 12, 2024 by
Nathan Gray, CRTonline.org

One of the biggest advantages in the standardized use of cardiac computed tomography (CCT) in pre- and post-left atrial appendage occlusion (LAAO) may be the substantial value for it to provide reproducible standardization and in-depth evaluation of LAAO devices for scientific advancement and research design and development, a new review suggests.

LVWS and LV Remodeling Characterize Aortic Stenosis and Mitral Regurgitation: Single-Center Study

Aug 05, 2024 by
Will Chu, CRTonline.org

Aortic stenosis (AS) and mitral regurgitation (MR) are characterized by different left ventricular wall stress (LVWS) and left ventricular (LV) remodeling, a new study finds, which assesses the effect MitraClip (MC) and transcatheter aortic valve replacement (TAVR) have on LVWS.

Breaking News: Edwards Lifesciences to Acquire JenaValve and Endotronix

Jul 24, 2024 by
Bailey Salimes, CRTonline.org

(BUSINESS WIRE) Edwards Lifesciences agreed to acquire JenaValve Technology and Endotronix on Wednesday, adding to their structural heart portfolio.

Systematic Assessment and CT Analysis are Necessary to Determine Redo TAV Suitability: State-of-the-Art Review

Jul 22, 2024 by
Nathan Gray, CRTonline.org

By standardizing the workflow for patient assessment before implantation of a new transcatheter aortic valve (redo TAV), heart teams can better assess the feasibility of redo-TAV for any index TAV, as well as identify patients anatomically unsuitable or suboptimal for this procedure, a new review suggests.

Evolut Device Demonstrates Low All-Cause Mortality Rates in TAVR Patients, Study Finds

Jul 22, 2024 by
Will Chu, CRTonline.org

New trial findings suggest that patients with severe bicuspid valve aortic stenosis (AS), who underwent transcatheter aortic valve replacement (TAVR) with the Evolut (Medtronic) bioprosthesis, demonstrates lower rates of all-cause mortality or disabling stroke.

Severe Aortic Wall Thrombus in TAVR Patients Linked to Thromboembolic Complications, Including Stroke

Jul 22, 2024 by
Nathan Gray, CRTonline.org

The presence of severe aortic wall thrombus (AWT) on pre-procedural multidetector computed tomography (CT) is strongly associated with thromboembolic complications, including stroke and mortality, in patients undergoing transfemoral (TF) transcatheter aortic valve replacement (TAVR), an analysis of patient data reports.

Controversial SuAVR Procedures Could Have Midterm Advantages, But Longterm Outcomes Are Unclear: State-of-the-Art Review

Jul 15, 2024 by
Natalie Morrison, CRTonline.org

Sutureless aortic valves appear to have some midterm advantages versus surgical and transcatheter aortic valve replacement, including reduced surgery time, but long-term outcomes are still unclear, according to a new meta-analysis of observational evidence.

Mediterranean Diet Linked to Lower All-Cause and CV Mortality Among Cancer Survivors, Study Concludes

Jul 08, 2024 by
Will Chu, CRTonline.org

Maintaining or adopting a traditional Mediterranean Diet (MD), even after a cancer diagnosis, may be beneficial, says a new study, which attributes the regimen’s health benefits to its blend of anti-inflammatory, antioxidant and antitumor compounds.

Joint Management of HFpEF and Tricuspid Regurgitation May Drive Improved Outcomes: State-of-the-Art Review

Jul 01, 2024 by
Nathan Gray, CRTonline.org

A better understanding of the interplay between heart failure with preserved ejection fraction (HFpEF) and tricuspid regurgitation (TR) could lead to more refined management strategies that address both conditions simultaneously, according to a new review.

Non-White Pediatric Cardiac Surgery Patients at Greater Risk for Mortality, Longer Hospital Stay: Cross-Sectional Study

Jun 12, 2024 by
Bailey Salimes, CRTonline.org

Non-white children and neonates who undergo cardiac surgery are at greater risk for mortality and longer postoperative length of hospital stay, a new analysis from the Pediatric Health Information System Database shows.

Non-Calcific TAV Degeneration ‘Should Be Taken into Consideration,’ Reports Analysis of Explanted Valves

Jun 10, 2024 by
Nathan Gray, CRTonline.org

Functional stenosis can occur in transcatheter aortic valves (TAVs) in the absence of obvious and significant calcification, according to an analysis of explanted TAVs that recommends the non-calcific degeneration of TAVs should be taken into consideration when evaluating TAV performance and lifetime management.

Research Suggests Social Health Determinants Linked to Mortality After Congenital Heart Surgery

Jun 10, 2024 by
Will Chu, CRTonline.org

Social determinants of health (SDoH) such as inequity in care access and systemic bias are associated with operative and longitudinal mortality after congenital heart surgery, new research suggests.

New Permanent Pacemaker After TAVR Does Not Impact 5-Year Clinical Outcomes: Registry Data

Jun 10, 2024 by
Nathan Gray, CRTonline.org

New permanent pacemaker (PPM) within 30 days of transcatheter aortic valve replacement (TAVR), remains a frequent complication in patients with aortic stenosis (AS), with identifiable clinical, electrocardiogram (ECG) and imaging predictors. However, new PPM is not associated with worse 5-year clinical outcomes, including mortality, reports a new analysis of registry data.

Cerebral Embolic Protection During TAVR Shows ‘Borderline Significant Reduction’ in Disabling Stroke: TVT Registry Analysis

Jun 05, 2024 by
Jason Wermers, CRTonline.org

Patients who are discharged to a facility after undergoing transcatheter aortic valve replacement (TAVR) are more likely to have experienced disabling stroke than those discharged home, a new study finds.

Stage Classification for AS Helps Mitigate Sex-Specific Differences in Cardiac Damage: Analysis

May 27, 2024 by
Nathan Gray, CRTonline.org

While patterns of upstream cardiac damage do differ between the sexes, a staging classification proved effective in the stratification of 5-year outcomes in both women and men with aortic stenosis (AS), according to a new analysis of patient data.

Transcatheter Sinus Venosus Defect Closure Achieves 97% Procedural Success Rate, Study Concludes

May 27, 2024 by
Will Chu, CRTonline.org

Transcatheter sinus venosus defect (SVD) closure carries a procedural success rate of 97%, according to a new study, which noted that the use of long, premounted, covered stents simplified the procedure.

ViV-TAVR Shows Similar Mortality at 2 Years, but Higher at 5 Years, vs. Redo SAVR: Analysis

May 22, 2024 by
Bailey Salimes, CRTonline.org

Patients who undergo valve-in-valve transcatheter aortic valve replacement (ViV-TAVR), have fewer periprocedural complications and similar rates of all-cause mortality at 2 years as compared with redo surgical aortic valve replacement (SAVR), a new retrospective study shows.

Lifetime Management for Congenital Heart Disease Offers New Opportunities for Improved Outcomes: Scientific Statement

May 20, 2024 by
Nathan Gray, CRTonline.org

Evolving technology and treatment options for congenital heart disease (CHD) can provide opportunities to dramatically alter patient prognosis; however, better identification of those at lifetime risk of preventable or treatable outcomes is central to such improvement, according to a new scientific statement.

AltaValve TMVR Device Shows Clinical, Procedural Benefits at 6 Months: EFS

May 16, 2024 by
Bailey Salimes, CRTonline.org

In patients with symptomatic, severe mitral regurgitation (MR) undergoing transcatheter mitral valve replacement (TMVR), the AltaValve system shows sustained clinical benefits, reduction of MR and potential treatment strategies for several mitral valve (MV) anatomies, according to the updated results from the AltaValve early feasibility study (EFS).

TAVR Shows Similar Long-Term Death or Disabling Stroke Risk, Higher Pacemaker Need, vs. SAVR: Meta-Analysis

May 16, 2024 by
Bailey Salimes, CRTonline.org

Patients with severe aortic stenosis (AS) who undergo transcatheter aortic valve replacement (TAVR) are at greater risk of needing pacemaker implantation, compared with patients who undergo surgical aortic valve replacement (SAVR), a new meta-analysis of seven trials shows.

ShortCut Device Meets Initial Safety, Efficacy Endpoints in Patients at High Risk for Coronary Obstruction: Pivotal Study

May 16, 2024 by
Bailey Salimes, CRTonline.org

In patients who are set to undergo transcatheter aortic valve replacement (TAVR) and are at-risk for coronary obstruction, the ShortCut leaflet modification device is safe and achieves success in leaflet splitting, and is associated with positive clinical outcomes, a new study shows.

TEER Shows Durable Outcomes, Comparable Survival to Tricuspid Valve Surgery at 1 Year in Primary TR: Registry Analysis

May 16, 2024 by
Jason Wermers, CRTonline.org

In patients with symptomatic, severe primary tricuspid regurgitation (TR), transcatheter edge-to-edge repair (TEER) and isolated tricuspid valve surgery showed comparable 1-year survival, and TEER’s procedural safety and efficacy outcomes were sustained through 1 year, a new registry analysis shows.

TRIGISTRY Analysis: 1-Year Survival Drops as Post-TTV Repair Residual TR Rises

May 16, 2024 by
Jason Wermers, CRTonline.org

The 1-year survival rate of patients who underwent transcatheter tricuspid valve (TTV) repair to treat severe, symptomatic tricuspid regurgitation (TR) dropped as the grade of residual TR at discharge increased, according to a new registry analysis.

MiCLASP Analysis: TEER with PASCAL Shows Positive Results at 1 Year in FMR Patients

May 16, 2024 by
Jason Wermers, CRTonline.org

Patients with functional mitral regurgitation (FMR) who underwent transcatheter edge-to-edge repair (TEER) with a PASCAL device showed durable MR reduction, a high survival rate and low incidence of major adverse events, and sustained functional and quality-of-life improvements, a new analysis shows.

LANDMARK Trial: Myval Noninferior to Contemporary THVs in Treating Native Aortic Stenosis

May 15, 2024 by
Jason Wermers, CRTonline.org

The novel balloon-expandable Myval transcatheter heart valve (THV) demonstrated noninferiority to contemporary THVs in patients with severe native aortic stenosis, new randomized trial results show.

NOTION-2: TAVR, SAVR Show Similar Results in Younger, Low-Surgical-Risk Patients

May 15, 2024 by
Jason Wermers, CRTonline.org

A randomized trial that sought to include younger, low-surgical risk patients with severe, symptomatic aortic stenosis (AS) and those with bicuspid aortic valves showed similar results between transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR).

FFR-Guided PCI with TAVR Beats CABG with SAVR in Concomitant Severe AS, Complex CAD: TCW Trial

May 14, 2024 by
Jason Wermers, CRTonline.org

A strategy of fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) and transcatheter aortic valve replacement (TAVR) demonstrated significantly lower event rates, including mortality, at 1 year, than a strategy of coronary artery bypass graft (CABG) and surgical aortic valve replacement (SAVR), in patients with concomitant complex coronary artery disease (CAD) and severe aortic stenosis (AS), new randomized trial results show.

Self-Expanding Valve Clinically Noninferior, Functionally Superior to Balloon-Expandable Valve at 1 Year in Women: SMART Trial Analysis

May 14, 2024 by
Jason Wermers, CRTonline.org

Women with small aortic annuli who underwent transcatheter aortic valve replacement (TAVR) with a self-expanding valve showed similar clinical results and significantly better valve function through 1 year as compared with those whose procedure involved a balloon-expandable valve, a new analysis of the SMART Trial shows.

Physicians Must Rule Out Surgically Occluded LAA Before Anticoagulation, Warns Research Letter

May 06, 2024 by
Nathan Gray, CRTonline.org

Surgically occluded left atrial appendages (LAAs) were identified in 14% of patients with a history of atrial fibrillation and open-heart surgery, with incomplete LAA closure in 1 of 5 patients, new patient data report.

SMART Trial Analysis Confirms SEV’s Hemodynamic Superiority Over BEV in Aortic Stenosis Patients with Small Annuli

May 03, 2024 by
Will Chu, CRTonline.org

A new analysis of the SMART trial suggests that self-expanding valves (SEVs) are hemodynamically superior to balloon-expandable valves (BEVs) in aortic stenosis patients with small aortic annuli undergoing transcatheter aortic valve replacement (TAVR).

Tricuspid Annuloplasty Alongside Mitral Valve Repair Linked to Pacemaker Implantation, Subsequent Risk

Apr 22, 2024 by
Nathan Gray, CRTonline.org

Among patients undergoing mitral valve repair (MVR), the addition of tricuspid annuloplasty (TA) is associated with a higher incidence of permanent pacemaker (PPM) implantation, and subsequently linked with reduced long-term survival and higher rates of heart failure hospitalization and infective endocarditis, an analysis of patient data shows.

Exercise, Protein Supplementation Improve Physical Functioning in Older, Frail Patients Undergoing TAVR: Trial

Apr 08, 2024 by
Bailey Salimes, CRTonline.org

A combination of home-based exercise and protein supplements improves 12-week physical performance in frail, older adults who are undergoing transcatheter aortic valve replacement (TAVR), a new study shows.

TAVR Noninferior to SAVR for All-Cause Mortality, Stroke at 1 Year in Low- to Intermediate-Risk Patients: DEDICATE

Apr 08, 2024 by
Jason Wermers, CRTonline.org

Transcatheter aortic valve replacement (TAVR) with operator’s choice of prosthesis was noninferior to surgical aortic valve replacement (SAVR) concerning the composite of all-cause mortality or stroke at 1 year in patients with severe, symptomatic aortic stenosis at low to intermediate surgical risk, new randomized trial data show.

Restricting Benzodiazepine Use Does Not Reduce Delirium After Cardiac Surgery: B-FREE Trial

Apr 07, 2024 by
Bailey Salimes, CRTonline.org

Postoperative delirium incidence is not reduced while restricting benzodiazepines during cardiac surgery, according to an intention-to-treat analysis.

SMART Trial: Self-Expanding THV Noninferior to Balloon-Expandable THV for Clinical Outcomes, Superior for Valve Dysfunction Through 1 Year

Apr 07, 2024 by
Jason Wermers, CRTonline.org

Transcatheter aortic valve replacement (TAVR) with a supra-annular, self-expanding valve (SEV) was noninferior to TAVR with an intra-annular, balloon-expandable valve (BEV) with regard to clinical outcomes, and superior concerning bioprosthetic valve dysfunction, through 12 months in patients with symptomatic, severe aortic stenosis who have small aortic annuli, the SMART Trial shows.

TriClip Receives FDA Approval to Treat Tricuspid Regurgitation

Apr 02, 2024 by
Jason Wermers, CRTonline.org

The U.S. Food and Drug Administration (FDA) has approved Abbott’s TriClip Transcatheter Tricuspid Valve Repair System to treat tricuspid regurgitation (TR), the device manufacturer announced Tuesday.

Real-World Study Shows Promising Results for Harmony TPV

Apr 01, 2024 by
Lior Lupu, MD, MBA

A large multicenter real-world experience with the self-expanding Harmony valve for transcutaneous pulmonary valve replacement (TPVR) shows excellent clinical and hemodynamic outcomes through more than 1 year of follow-up.

Protego Shield Provides Lead Apron Alternative With ‘Exceptional Total Body’ Radiation Protection, Study Finds

Mar 12, 2024 by
Will Chu, CRTonline.org

The Protego shield provides protection from total body radiation exposure (RE) for operators performing coronary and structural heart procedures, allowing procedural performance without the need for personal lead aprons, a new study finds.

Sustained Hemodynamic Outcomes in TAVR Compared With Contemporary SAVR Valves: Evolut Low Risk Substudy

Mar 11, 2024 by
Bailey Salimes, CRTonline.org

At 4 years post-transcatheter aortic valve replacement (TAVR), patients who received the CoreValve, Evolut R or Evolut PRO self-expanding valves continued to show robust clinical outcomes, and better hemodynamic outcomes, in comparison with patients who underwent surgical aortic valve replacement (SAVR) with contemporary surgical valves, a new analysis shows.

Edge-to-Edge Valvular Intervention for Mixed Valvular Disease Could Improve Patient Outcomes, Study Concludes

Mar 11, 2024 by
Will Chu, CRTonline.org

The potential benefit of a staged edge-to-edge valvular intervention for mixed valvular heart disease (VHD) could improve outcomes in patients with persistent severe VHD post-transcatheter aortic valve replacement (TAVR).

JenaValve THV Has Good Acute Performance in Severe AR: International Study

Mar 11, 2024 by
Bailey Salimes, CRTonline.org

In patients with severe aortic regurgitation (AR), the purpose-built JenaValve Trilogy transcatheter heart valve (THV) system has better acute performance when used off-label compared with other THVs, a retrospective analysis shows

Novel AltaValve TMVR Device Shows High Technical Success, Promising Early Clinical Outcomes in EFS

Mar 11, 2024 by
Jason Wermers, CRTonline.org

The AltaValve System, a novel atrial-fixation transcatheter mitral valve replacement (TMVR) device, showed high technical success with clinically significant reduction in mitral regurgitation (MR), new study data show.

20-mm BEVs Have Similar Mortality Rates to Larger BEVs: TVT Registry Analysis

Mar 11, 2024 by
Bailey Salimes, CRTonline.org

Use of 20-mm Sapien 3 balloon-expandable valves (BEVs) is associated with higher discharge echocardiography-derived mean gradients (MGs) compared with use of BEVs ≥23 mm, but they have similar 3-year patient mortality rates, a new registry analysis of the shows.

EMERGE Study: As Operators Gain Experience with Amulet LAAO Device, Success Increases and Adverse Events Drop

Mar 11, 2024 by
Jason Wermers, CRTonline.org

The Amulet left atrial appendage (LAA) occluder (Abbott) shows that procedural success rates improved and periprocedural complications dropped as operators learned how to use the device, according to new results from the EMERGE LAA study.

Navitor Valve Is Safe, Effective for High- or Extreme-Surgical-Risk Patients With AS: Navitor IDE Study

Mar 11, 2024 by
Bailey Salimes, CRTonline.org

High- and extreme-surgical-risk patients with severe, symptomatic aortic stenosis (AS) who receive the Navitor system have a lower 1-year mortality rate compared with commercially approved contemporary transcatheter aortic valve implantation (TAVI) devices, a new study shows.

TAVR Provides Economic Value Over SAVR, Reports Updated Cost-Effectiveness Analysis

Mar 11, 2024 by
Nathan Gray, CRTonline.org

Transcatheter aortic valve replacement (TAVR) using the Evolut valve is projected to provide high economic value compared with surgical aortic valve replacement (SAVR) for low-risk patients, largely driven by improved survival, according to an updated cost-effectiveness analysis using new 4-year data.

3D-ICE Is Safe, Effective in Mitral TEER Early Feasibility Trial

Mar 10, 2024 by
Bailey Salimes, CRTonline.org

Three-dimensional intracardiac echocardiography (3D-ICE) demonstrated safety and effectiveness in guiding mitral valve transcatheter edge-to-edge repair (TEER) procedures with MitraClip to treat mitral regurgitation (MR), according to new early feasibility study results.

Laguna Tech Alpha, Zeta Valves Effective in Addressing Aortic Valve Disease, Study Suggests

Mar 10, 2024 by
Will Chu, CRTonline.org

A study suggests that features of the Laguna Tech Alpha and Zeta aortic valve replacement systems contribute to a successful implantation in patients with all types of aortic valve disease, even without calcium.

J-Valve Shows Favorable Safety through 30 Days in EFS

Mar 10, 2024 by
Jason Wermers, CRTonline.org

The novel J-Valve Transfemoral transcatheter heart valve (THV) showed favorable procedural and 30-day safety in the treatment of aortic regurgitation (AR), with no cardiovascular- or device-related death, no disabling stroke and no residual AR, according to a new study.

DurAVR THV Shows Early Favorable Safety, Hemodynamic Stability in Patients With Severe AS

Mar 10, 2024 by
Bailey Salimes, CRTonline.org

The Anteris DurAVR biomimetic transcatheter heart valve (THV) demonstrated outstanding hemodynamic performance in patients with severe, symptomatic aortic stenosis (AS) who received the device in an early feasibility study (EFS).

Early Emory Data Report Technical Success for Novel SESAME Transcatheter Electrosurgical Procedure

Mar 10, 2024 by
Nathan Gray, CRTonline.org

First-in-human data for a novel transcatheter electrosurgical procedure developed to mimic surgical myotomy suggest it may provide benefit to patients requiring septal reduction therapy for obstructive hypertrophic cardiomyopathy (HCM).

CT Simulation Study: Severe Coronary Overlap Rare When Commissural Alignment Is Used in TAVR

Mar 06, 2024 by
Bailey Salimes, CRTonline.org

A computed tomography (CT) simulation of transcatheter aortic valve replacement (TAVR) procedures concludes that the incidence of coronary overlap with transcatheter heart valve commissure is rare when commissural or coronary alignment is used.

Small Study Finds 5.5% Coronary Cannulation Failure Rate Post-TAVR with Self-Expanding THVs

Mar 06, 2024 by
Bailey Salimes, CRTonline.org

In patients who underwent transcatheter aortic valve replacement (TAVR) with self-expanding transcatheter heart valves (THVs) using commissural alignment (CA) techniques, coronary artery cannulation was unsuccessful in 5.5%, new study results show.

TriACT Registry: TTVR Shows Greater TR Reduction, Procedural Complications vs. T-TEER in Functional TR Patients

Feb 26, 2024 by
Dan Haberman, MD, CRTonline.org

Screening failure for transcatheter tricuspid valve replacement (TTVR) is high at 74%, mainly related to large tricuspid annular diameter, but tricuspid regurgitation (TR) reduction is superior with TTVR compared with tricuspid transcatheter edge-to-edge repair (T-TEER) and optimal medical therapy (OMT), a new registry analysis shows.

Alain Cribier, TAVR Pioneer: 1945-2024

Feb 22, 2024 by
Jason Wermers and Bailey Salimes, CRTonline.org

Alain Cribier, MD, an interventional cardiology pioneer who implanted the first bioprosthetic transcatheter aortic valve, died Friday. He was 79.

Infective Endocarditis Surgery Effective in Persons Who Inject Drugs, but Addiction Is Far More Lethal than Infection: Retrospective Analysis

Feb 19, 2024 by
Bailey Salimes, CRTonline.org

Surgery for infective endocarditis can be safely performed with low mortality rates in persons who inject drugs (PWID), but addiction to the drugs themselves is extremely lethal – much more so than the surgery – a new study reveals.

FDA Panel Backs TriClip G4 TEER Device for Symptomatic, Severe TR

Feb 13, 2024 by
Jason Wermers, CRTonline.org

The TriClip G4 transcatheter edge-to-edge repair (TEER) device received a strong endorsement Tuesday from a U.S. Food and Drug Administration (FDA) advisory panel.

Study: Fontan-Associated Liver Disease, Advanced Fibrosis Associated with Increased Inflammatory Gene Expression

Feb 12, 2024 by
Jason Wermers, CRTonline.org

Patients with Fontan-associated liver disease (FALD) and advanced fibrosis or a composite clinical outcome expressed upregulated genes related to inflammation, congestion and angiogenesis, a new study shows.

Abbott’s Amplatzer Amulet Device Shows Favorable Safety, Efficacy in Patients Undergoing LAAO: EMERGE Study

Feb 02, 2024 by
Bailey Salimes, CRTonline.org

The Amplatzer Amulet occluder (Abbott) device proves both safe and effective in the real-world setting, and operators who have more experience also have higher rate of implant success, the EMERGE Left Atrial Appendage study demonstrates.

FDA Approves EVOQUE as First Transcatheter Treatment for TR

Feb 02, 2024 by
Jason Wermers, CRTonline.org

The EVOQUE Tricuspid Valve System is the first device to receive U.S. Food and Drug Administration (FDA) approval for transcatheter therapy of tricuspid regurgitation (TR), manufacturer Edwards Lifesciences announced Friday.

2 New Biomarkers Show Potential in Assessing Aortic Stenosis – Cross-Sectional Analysis

Jan 29, 2024 by
Dan Haberman, MD, CRTonline.org

Of 52 circulating proteins significantly associated with both aortic valve (AV) hemodynamics and aortic stenosis (AS) severity, according to echocardiographic parameters, two show potential in assessing AS risk and treatment, a new study shows.

Transcatheter Pulmonary Valve Replacement Increased in US Since 2010

Jan 22, 2024 by
Waiel Abusnina, MD, CRTonline.org

Transcatheter pulmonary valve replacement (TPVR) has increased since it was approved in the U.S. in 2010 to treat regurgitant native right ventricular outflow tract (RVOT) anatomy, and the SAPIEN valve is the most commonly used device in recent years, according to a new analysis of real-world data.

COAPT-Ineligible FMR Patients Show Higher 1-Year Death, HF Hospitalization vs. COAPT-Eligible Patients: TVT Registry Analysis

Jan 22, 2024 by
Pavan Reddy, MD, CRTonline.org

An analysis of patient outcomes after mitral transcatheter edge-to-edge repair (M-TEER) shows that patients with functional mitral regurgitation (FMR) ineligible for the COAPT trial had a lower rate of technical procedural success and higher rates of 1 year death and heart failure hospitalization (HFH) as compared with COAPT-eligible patients.

Transcatheter Pulmonary Valve Replacement Shows More Favorable Reverse Remodeling, Higher Endocarditis Risk vs. Surgery

Jan 22, 2024 by
Kalyan R. Chitturi, DO, CRTonline.org

Transcatheter pulmonary valve replacement (TPVR) was associated with favorable right heart reverse remodeling compared to surgical pulmonary valve replacement (SPVR), though at the cost of worse long-term prosthesis durability, primarily due to an increased risk of prosthetic valve endocarditis, a new study shows.

LAAO with Concomitant Procedures Shows Similar Clinical Outcomes to Isolated LAAO: US National Database Analysis

Jan 22, 2024 by
Ilan Merdler, MD, MHA, CRTonline.org

A new study suggests that combining left atrial appendage occlusion (LAAO) with another cardiac intervention is linked to similar major adverse cardiovascular events (MACE) and length of stay (LOS), albeit at a higher cost, as compared with LAAO alone.

APPROACH-IS Substudy: Decreased QOL, Increased Anxiety, Depression in Adults With Congenital Heart Disease

Jan 15, 2024 by
Bailey Salimes, CRTonline.org

Nearly one third of adults with congenital heart disease (CHD) report higher rates of depression or anxiety, which is associated with a lower quality of life (QOL) and health status (HS), as shown in a new global substudy of the APPROACH-IS trial.

Call for Sex-Specific Guidelines as Study Highlights Gender Differences in Mitral Valve Surgery Outcomes

Jan 08, 2024 by
Nathan Gray, CRTonline.org

Compared with men, women face a higher risk of death after mitral valve surgery for severe degenerative mitral regurgitation (MR), at smaller left ventricular end-systolic dimension (LVESD) and higher ejection fraction (EF), a new analysis of patient data suggests.

DOACs Lower Risk of Complications and Shorten Hospital Stay after TMVR vs. VKAs: Study

Jan 08, 2024 by
Nathan Gray, CRTonline.org

Treatment with target-specific direct oral anticoagulants (DOACs) after transcatheter mitral valve replacement (TMVR) is associated with a lower risk of bleeding than anticoagulation with vitamin K antagonists (VKAs), without a significant increase in the risk of thrombotic events, new patient data suggest.

Atrial Function TR Predicts TR Persistence, Aggravation in TAVR Patients, Study Suggests

Jan 08, 2024 by
Will Chu, CRTonline.org

Atrial functional tricuspid regurgitation (afTR) is a predictor for tricuspid regurgitation (TR) persistence and aggravation in transcatheter aortic valve replacement (TAVR) patients, a study suggests.

Swiss Registry Analysis: Long-Term Stroke Risk in TAVR Patients Higher at 2 Years Post-Procedure vs. General Population

Dec 25, 2023 by
Will Chu, CRTonline.org

The long-term risk of stroke in patients after transcatheter aortic valve replacement (TAVR) is higher for up to 2 years post-procedure, with a comparable risk thereafter, to an age- and sex-adjusted general population, a new registry analysis shows.

TAVR-Related Subclinical Aortic Valve Thrombus Unrelated to Cerebral Events: ADAPT-TAVR Analysis

Dec 25, 2023 by
Nathan Gray, CRTonline.org

Subclinical aortic valve complex thrombus was common in patients who had undergone successful transcatheter aortic valve replacement (TAVR), but there was no significant relationship with new cerebral thromboembolism or neurologic or neurocognitive outcomes, according to a new pre-specified analysis of data from the ADAPT-TAVR trial.

Bleeding Complications Remain ‘Frequent and Important’ in Patients Undergoing Transfemoral TAVR

Dec 25, 2023 by
Nathan Gray, CRTonline.org

Despite important advancements over the past decade, bleeding remains frequent and potentially fatal in patients undergoing transfemoral transcatheter aortic valve replacement (TAVR), according to a new analysis of pooled patient-level trial data.

Baseline RV Function Unrelated to Symptomatic Improvement After M-TEER for MR: Observational Study

Dec 20, 2023 by
Kalyan R. Chitturi, DO, CRTonline.org

The presence of right ventricular dysfunction (RVD) was unrelated to symptomatic outcomes after mitral transcatheter-edge-to-edge repair (M-TEER), according to a single-center study.

IVL-Facilitated Percutaneous Balloon Mitral Valvuloplasty Feasible for Patients With Severe MAC: Single-Center Experience

Dec 20, 2023 by
Bailey Salimes, CRTonline.org

Patients with severe mitral annular calcification (MAC) who cannot undergo surgery are able to safely receive intravascular lithotripsy (IVL)-facilitated percutaneous balloon mitral valvuloplasty (PBMV), a new study reveals.

Danish Study: PVR Procedure Volume Grew in Past 45 Years

Dec 20, 2023 by
Lior Lupu, MD, MBA, CRTonline.org

The procedural volume of pulmonary valve replacement (PVR) in patients with tetralogy of Fallot (TOF) has increased significantly over the last 45 years, according to an analysis of Danish national registry data.

Study: Infective Endocarditis Mortality Rates in US Increase in Young Adults, Decrease Overall

Dec 13, 2023 by
Bailey Salimes, CRTonline.org

Infective endocarditis (IE) age-adjusted mortality rates have declined in the last 20 years, but mortality in 25- to 44-year-olds has increased over that time, especially in Kentucky, Tennessee and West Virginia, leading the investigators to speculate that the opioid crisis has contributed to these findings, a new analysis shows.

Mitral Annular Disjunction Is a ‘Clinically Meaningful’ Factor in TEER for DMR

Dec 11, 2023 by
Nathan Gray, CRTonline.org

Mitral annular disjunction (MAD) is “highly prevalent” in patients undergoing transcatheter edge-to-edge repair (TEER) for degenerative mitral regurgitation (MR) and may be linked to worse clinical outcomes, according to new patient cohort data.

TricValve System Shows Promising 1-Year Results in Treating Severe TR

Dec 06, 2023 by
Bailey Salimes, CRTonline.org

New results from the TRICUS and TRICUS EURO studies show that, at 1 year, quality of life (QoL) was significantly improved in patients with severe tricuspid regurgitation (TR) who received the TricValve system via heterotopic caval valve implantation.

Post-LAA Closure DRT Should Be Managed as Chronic Condition Until Regression, Concludes Study

Nov 27, 2023 by
Will Chu, CRTonline.org

Device-related thrombus (DRT) should be addressed as a chronic condition, says a new study, which identifies a larger initial DRT size as the only independent predictor of the complication’s evolution.

Retrospective Study Reports ‘Satisfactory’ Long-Term Outcomes for SAVV Surgery in ccTGA Patients

Nov 27, 2023 by
Nathan Gray, CRTonline.org

Systemic atrioventricular valve (SAVV) surgery remains a “valuable option” for the management of patients with congenitally corrected transposition of the great arteries (ccTGA), with low early mortality and satisfactory long-term outcomes, particularly in those with systemic ventricular ejection fraction (SVEF) of 40% or greater, reports a new retrospective analysis of patient data.

New Congenital Heart Surgery Risk-Adjustment Model Exhibits ‘Excellent Predictive Ability’ in Patient Outcomes

Nov 27, 2023 by
Will Chu, CRTonline.org

A newly developed stratification model for congenital heart surgery (CHS) exhibits “excellent predictive ability” that accounts for patient and procedural characteristics associated with in-hospital mortality, according to the authors of a new study.

Registry Analysis: Nearly Half of T-TEER Patients Did Not Meet TRILUMINATE Trial Eligibility Criteria

Nov 20, 2023 by
Jason Wermers, CRTonline.org

Nearly half of patients with severe tricuspid regurgitation (TR) in a real-world registry analysis did not meet eligibility criteria for the TRILUMINATE randomized trial, suggesting “limited generalizability” of the trial to a real-world setting, new study results show.

New-Generation SAPIEN 3 Ultra Resilia Shows Superior Post-TAVR Hemodynamics to SAPIEN 3 – OCEAN-TAVI Registry Analysis

Nov 19, 2023 by
Bailey Salimes, CRTonline.org

Early echocardiographic results of patients undergoing transcatheter aortic valve replacement (TAVR) with the new-generation SAPIEN 3 Ultra Resilia (S3UR) balloon-expandable transcatheter heart valve (THV) show superior hemodynamic performance compared to the SAPIEN 3 (S3) device.

Deep Learning Echo Predicts Left Heart Structure, Function, Associated Clinical Outcomes: Study

Nov 06, 2023 by
Bailey Salimes, CRTonline.org

Left heart structure and function, as well as some clinical outcomes, can be accurately quantified by interpreting deep-learning echocardiography, a new study shows.

TAVR LBBB Falling in US, but Associated with Worse Clinical Outcomes at 1-Year – Registry Analysis

Oct 26, 2023 by
Kalyan R. Chitturi, DO, CRTonline.org

The incidence of post-transcatheter aortic valve replacement (TAVR) new left bundle branch block (LBBB) has dropped in the past 5 years in the U.S., but when it does happen, post-TAVR LBBB is associated with adverse clinical outcomes at 1 year, a new study shows.

Intraprocedural EP Study During TAVR Can Identify Patients at Risk of High-Grade AV Block, Study Shows

Oct 26, 2023 by
Abhishek Chaturvedi, MD, CRTonline.org

Among patients undergoing transcatheter aortic valve replacement (TAVR), an intraprocedural electrophysiology study (EPS) can identify those at risk of early and delayed high-grade atrioventricular (AV) block post-TAVR, according to a new study.

Full PASCAL IID Trial Results Confirm Noninferiority of PASCAL to MitraClip in Prohibitive-Risk DMR Patients

Oct 26, 2023 by
Jason Wermers, CRTonline.org

SAN FRANCISCO – The full cohort of the CLASP IID randomized controlled trial continued to show noninferiority of transcatheter edge-to-edge repair (TEER) with the PASCAL system to TEER with the MitraClip system in prohibitive-surgical-risk patients with degenerative mitral regurgitation (DMR), new results show.

Both TAVR, SAVR Valid for Patients with Small Aortic Annuli: VIVA Randomized Trial

Oct 26, 2023 by
Bailey Salimes, CRTonline.org

SAN FRANCISCO – A new randomized controlled trial did not show differences in hemodynamic results between transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in a mostly female patient population with severe aortic stenosis (AS) and small aortic annuli (SAA).

Severe TR Patients Report Improved Health Outcomes at 1 Year Post-T-TEER With TriClip – TRILUMINATE Analysis

Oct 26, 2023 by
Bailey Salimes, CRTonline.org

SAN FRANCISCO – Patients with severe tricuspid regurgitation (TR) have sustained health improvement when undergoing tricuspid valve transcatheter edge-to-edge repair (T-TEER) with the TriClip system compared with patients who undergo medical therapy alone, a secondary analysis of the TRILUMINATE Pivotal trial shows.

Transcatheter Tricuspid Valve Replacement with EVOQUE Shows Feasibility, Safety – Early TRISCEND II Results

Oct 26, 2023 by
Jason Wermers, CRTonline.org

SAN FRANCISCO – The EVOQUE Transcatheter Tricuspid Valve Replacement System demonstrated an acceptable safety profile in a highly comorbid patient population with severe tricuspid regurgitation (TR) and eliminated TR in most patients, a new study shows.

Early Trial Results Show Promise for TMVR with Tendyne Device

Oct 24, 2023 by
Bailey Salimes, CRTonline.org

SAN FRANCISCO – Roll-in patients with symptomatic mitral regurgitation (MR) or severe mitral annular calcification (MAC) who undergo transcatheter mitral valve replacement (TMVR) via the Tendyne System showed 100% procedural survival and maintained MR elimination through 1 year, as well as improved quality of life and heart failure symptoms, according to an early look at the SUMMIT Tendyne trial.

4th Generation MitraClip Device Safe and Effective at 1 year: EXPAND G4 Registry

Oct 24, 2023 by
Kalyan R. Chitturi, DO, CRTonline.org

Mitral transcatheter edge-to-edge repair (M-TEER) with the fourth generation MitraClip G4 system was safe and effective at 1 year, with durable reductions in mitral regurgitation (MR) severity in more than 90% of patients and concomitant improvement in functional status and quality of life, according to an ongoing prospective multicenter registry study.

SWISS-APERO Analysis: No Difference in 13-Month Outcomes for LAAC with Amulet or Watchman

Oct 24, 2023 by
Abhishek Chaturvedi, MD, CRTonline.org

Among patients undergoing clinically indicated left atrial appendage closure (LAAC) and in whom LAA anatomy was deemed suitable for either the Amulet or Watchman FLX device, there was no difference in device-related and clinical outcomes at 13 months, according to a prespecified analysis of the SWISS-APERO trial.

TEER with TriClip Shows Sustained TR Reduction in Patients with Complex Anatomies: TRILUMINATE Substudy

Oct 24, 2023 by
Waiel Abusnina, MD, CRTonline.org

Transcatheter edge-to-edge repair (TEER) of the tricuspid valve with the TriClip device in patients with complex tricuspid anatomy reduced the severity of tricuspid regurgitation (TR) and was associated with improvement in quality of life, according to a substudy of the TRILUMINATE pivotal trial.

JenaValve Trilogy Heart Valve Meets Initial Safety, Efficacy Endpoints for Patients with AR

Oct 24, 2023 by
Bailey Salimes, CRTonline.org

SAN FRANCISCO – Safety and efficacy outcomes were met in patients with severe, symptomatic aortic regurgitation (AR) who received the JenaValve Heart Valve System, a new study shows.

WATCH-TAVR: TAVR with LAAO Noninferior to TAVR with Medical Therapy in Aortic Stenosis with AFib

Oct 24, 2023 by
Bailey Salimes, CRTonline.org

SAN FRANCISCO – In patients with severe aortic stenosis with atrial fibrillation (AF), left atrial appendage occlusion (LAAO) with the Watchman 2.5 device and transcatheter aortic valve replacement (TAVR) is noninferior to TAVR with medical therapy, a new study shows.

PARTNER 3: TAVR with Balloon-Expandable Valve Shows Comparable Outcomes vs. SAVR in Low-Risk Patients at 5 Years

Oct 24, 2023 by
Jason Wermers, CRTonline.org

SAN FRANCISCO – Both transcatheter aortic valve replacement (TAVR) with a balloon-expandable valve and surgical aortic valve replacement showed similar clinical outcomes at 5 years post-procedure in low-surgical-risk patients, according to 5-year data from the PARTNER 3 trial.

SURPASS Registry Analysis: ICE, TEE Guidance Show Similar Success in LAAO

Oct 11, 2023 by
Bailey Salimes, CRTonline.org

When intracardiac echocardiography (ICE) is used for complete left atrial appendage occlusion (LAAO) sealing, the imaging modality shows a higher risk of pericardial effusion compared with transesophageal echocardiography (TEE), although the risk drops as operators gain more experience with ICE, according to a new registry analysis.

Observational Study: Advanced HF, SCD Account for 18% of Mortality at 2 Years Post-TAVR with Newer-Generation Devices

Sep 25, 2023 by
Kalyan R. Chitturi, DO, CRTonline.org

Advanced heart failure (HF) and sudden cardiac death (SCD) accounted for nearly a fifth of deaths at a median 2-year follow-up after transcatheter aortic valve replacement (TAVR) with newer-generation devices, according to a multicenter prospective cohort study, although HF-related death was reduced compared to a previous study of TAVR with older-generation devices.

TMVR with Balloon-Expandable Aortic Valve Has Favorable 5-Year Outcomes in ViV, ViR, ViMAC Patients, Trial Shows

Sep 25, 2023 by
Abhishek Chaturvedi, MD, CRTonline.org

In high-surgical-risk patients, mitral valve-in-valve (MViV), valve-in-ring (MViR), or valve-in-mitral annular calcification (ViMAC) procedures are associated with long-term improvement in heart failure symptoms and quality of life among survivors, according to findings from the MITRAL trial.

COAPT Post-Approval Study Shows Safety, Effectiveness of M-TEER with MitraClip

Sep 18, 2023 by
Lior Lupu, MD, MBA, CRTonline.org

The largest real-world prospective outcome study to date, including 5,000 consecutive heart failure (HF) patients with secondary mitral regurgitation (SMR), reinforces the safety and effectiveness of transcutaneous edge-to-edge repair (TEER) using the MitraClip System (Abbott).

High Postoperative hs-cTnT Associated with Higher 30-Day Mortality After Cardiac Surgery – Single-Center Retrospective Study

Sep 18, 2023 by
Waiel Abusnina, MD, CRTonline.org

Perioperative myocardial injury (PMI) after coronary artery bypass grafting (CABG) and other cardiac surgeries reflected by high perioperative high-sensitivity cardiac troponin T (hs-cTnT) is associated with high 30-day mortality, a new study shows.

Chronic Medication Usage Burdens Pediatric Cardiac Surgery Patients: New York Retrospective Analysis

Sep 18, 2023 by
Bailey Salimes, CRTonline.org

An increasingly high medication burden plagues children who undergo cardiac surgery, a new analysis shows.

Retrospective Study: Better Long-Term Survival Rates in Patients with Biventricular CHD vs. No CHD who Survive First Year Post-Heart Transplantation

Sep 11, 2023 by
Bailey Salimes, CRTonline.org

In patients with congenital heart disease (CHD) who undergo heart transplantation, single-ventricle physiology is associated with higher short-term mortality rates, a new study shows.

Pre-TAVR Workup PCI Increases Risk for Late Bleeding Events – Multicenter Study

Sep 11, 2023 by
Dan Haberman, MD, CRTonline.org

Patients undergoing percutaneous coronary intervention (PCI) during preprocedural transcatheter aortic valve replacement (TAVR) workup are at higher risk for late bleeding events (LBEs), defined as >30 days after TAVR, a new study shows.

Aortic Valve-Sparing Provides ‘Stable and Durable Function’ in Marfan Syndrome Patients – Long-Term Study

Sep 04, 2023 by
Will Chu, CRTonline.org

A new study of patients with Marfan syndrome (MS) suggests that aortic valve-sparing operations, specifically the reimplantation procedure, provide stable and durable aortic valve function.

Opportunity Index ‘Partially Explains’ Higher Mortality Rate Among Ethnic Children Post-CHD Surgery, Analysis Finds

Aug 21, 2023 by
Will Chu, CRTonline.org

A new analysis finds that children from the lowest Childhood Opportunity Index (COI) neighborhoods undergoing congenital heart disease (CHD) surgery had disproportionately higher in-hospital mortality and decreased short-term survival.

Amulet Occluder Usage Frees Up More Patients from OAC vs. Watchman Device, Analysis Suggests

Aug 14, 2023 by
Will Chu, CRTonline.org

Using an Amulet (Abbott) device to perform a left atrial appendage occlusion (LAAO) results in a higher percentage of patients free of oral anticoagulation (OAC) usage during long-term follow-up compared to the Watchman (Boston Scientific) device, a new trial analysis shows.

Depth of Device Implantation in LAAO Predicts Increased Risk for DRT – Multicenter Study

Aug 09, 2023 by
Bailey Salimes, CRTonline.org

Depth of device implantation in left atrial appendage occlusion (LAAO) is an independent risk factor for device-related thrombus (DRT), in which deeper, larger implantation predicts a higher likelihood of DRT, a new study shows.

Hypoplastic Pulmonary Arteries Do Not Impact Outcomes in Neonates with Symptomatic Tetralogy of Fallot – Analysis

Aug 08, 2023 by
Nathan Gray, CRTonline.org

Despite perception, the presence of hypoplastic pulmonary arteries (hPA) does not adversely impact outcomes in neonates with symptomatic tetralogy of Fallot (sTOF), new data suggest.

RV Global Longitudinal Strain a Predictor of Mortality in Ebstein Anomaly Patients: Registry Data

Jul 31, 2023 by
Nathan Gray, CRTonline.org

Measurement of right ventricular global longitudinal strain (RVGLS) is independently associated with all-cause and cardiovascular mortality in adults with Ebstein anomaly, and RVGLS has superior predictive value compared with conventional echocardiographic indices of right ventricular (RV) systolic function, new data suggest.

Class I Recall Issued for Impella Left-Sided Blood Pumps

Jul 27, 2023 by
CRTonline.org

Abiomed issued a recall for all Impella left-sided blood pumps because the devices’ instructions do not describe adequate precautions clinicians should take when treating patients undergoing transcatheter aortic valve replacement (TAVR), the U.S. Food and Drug Administration (FDA) announced Thursday.

Women with Mild-Moderate AS Have Slower Hemodynamic Progression Than Men, but Similar Long-Term All-Cause Mortality – Retrospective Study

Jul 26, 2023 by
Bailey Salimes, CRTonline.org

Women with mild to moderate aortic stenosis (AS) were more likely than men to have preserved left ventricular ejection fraction (LVEF) and concentric left ventricular hypertrophy, and women had slower hemodynamic progression of AS and lower rates of aortic valve replacement (AVR), a new retrospective cohort analysis shows.

Study Shows Observed ViV TAVR Valve Anatomy Differs from Virtual CT Predictions

Jul 19, 2023 by
Bailey Salimes, CRTonline.org

Transcatheter heart valve (THV) outflows are often overexpanded in patients who undergo postdilatation with noncompliant balloons, meaning that virtual stimulations systematically overestimate the reported anatomical distances in valve-in-valve (ViV) transcatheter aortic valve replacement (TAVR) with balloon-expandable valves, according to a single-center retrospective study.

New PPI After TAVR with SEVs Associated with Higher 1-Year Mortality Risk – Registry Analysis

Jul 19, 2023 by
Bailey Salimes, CRTonline.org

Patients undergoing transcatheter aortic valve replacement (TAVR) with contemporary self-expanding valves (SEVs) often require new permanent pacemaker implantation (PPI), which is associated with a higher mortality risk at 1 year post-procedure, according to a new registry analysis.

LAAO May Reduce Fall-Related Injury Severity vs DOACs in AF-Related Stroke Patients, Study Finds

Jul 17, 2023 by
Will Chu, CRTonline.org

A new study finds that patients with atrial fibrillation (AF)-related stroke treated by left atrial appendage occlusion (LAAO) show significantly reduced injury severity and shortened hospital length of stay after traumatic falls when compared to patients treated with direct oral anticoagulants (DOACs).

Post-TAVR RV-PA Uncoupling an Independent Predictor of Long-Term Mortality, Analysis Concludes

Jul 10, 2023 by
Will Chu, CRTonline.org

A new study suggests that postprocedural right ventricular-to-pulmonary artery (RV-PA) uncoupling is an independent predictor of long-term mortality in patients undergoing transcatheter aortic valve replacement (TAVR).

Screening Failure in Transcatheter Tricuspid Valve Repair: Study Calls for Earlier Referrals

Jul 10, 2023 by
Nathan Gray, CRTonline.org

A majority of transcatheter tricuspid valve repair (TTVr) screen failure patients are excluded due to tricuspid valve (TV), right atrial (RA), and right ventricular (RV) enlargement. However, a significant proportion are excluded due to clinical futility, according to new characterization data.

Next-Gen Evolut FX System Shows ‘Significant Improvement’ Over PRO+ That May Benefit Younger Patients, Study Finds

Jul 10, 2023 by
Will Chu, CRTonline.org

The latest-generation Evolut FX transcatheter aortic valve replacement (TAVR) system (Medtronic) offers favorable 30-day outcomes, according to a new study, which demonstrates the device’s significant improvements over its predecessor, Evolut PRO+.

SAPIEN 3 TAVR Shows Non-Inferiority to SAVR in Intermediate-Risk Patients: 5-Year Follow-Up Data

Jul 03, 2023 by
Nathan Gray, CRTonline.org

SAPIEN 3 transcatheter aortic valve replacement (TAVR) is non-inferior to surgical aortic valve replacement (SAVR) in intermediate-risk patients with severe aortic stenosis at 5 years, according to mid-term follow-up data.

TEER with Abbott’s MitraClip Linked to Increased Anticoagulation Efficacy in Preventing Cerebrovascular Events in HF Patients – COAPT Analysis

Jun 26, 2023 by
Will Chu, CRTonline.org

The 4-year-rate of cerebrovascular events (CVE) is similar in patients undergoing transcatheter edge-to-edge repair (TEER) plus guideline-directed medical therapy (GDMT) compared with GDMT alone, a new analysis finds.

Latest MitraClip System Offers MR Reduction to TEER-Excluded Patients: Abbott-Sponsored Study

Jun 26, 2023 by
Will Chu, CRTonline.org

Mitral transcatheter edge-to-edge repair (TEER) using the latest, fourth-generation MitraClip system (Abbott Vascular) provides significant mitral regurgitation (MR) reduction and quality of life (QoL) improvement in patients previously deemed unsuitable for the procedure.

Fourth-Gen MitraClip Associated With High MR Reduction Rates, Concludes Abbott-Sponsored Study

Jun 26, 2023 by
Will Chu, CRTonline.org

A new study looking at the fourth-generation MitraClip system (Abbott Vascular) has demonstrated its ability to reduce mitral regurgitation (MR) to 2+ or less in 98% of patients after 30 days in findings that include an excellent safety profile and the lowest all-cause mortality rate.

Ebstein Anomaly Survival Has Increased Since 2000, but Mortality Remains Significantly Higher vs. General Population – Registry

Jun 19, 2023 by
Nathan Gray, CRTonline.org

Mortality rates in patients with Ebstein anomaly (EA) have improved significantly in the past 2 decades; however, mortality remains higher compared with the general population and is dependent on the severity of EA, according to new registry data.

Pre-Procedure Imaging Associated with Increased Likelihood of LAAO Success, But No Impact on Adverse Events – Registry Data

Jun 12, 2023 by
Nathan Gray, CRTonline.org

Pre-procedure use of computed tomography (CT)/cardiac magnetic resonance (CMR) imaging is independently associated with a modest but statistically significantly increased likelihood of left atrial appendage occlusion (LAAO) implantation success, device success, and procedure success, but with no difference in major adverse events (MAE), new registry data suggest.

Predictions Underestimate Actual Patient-Prosthesis Mismatch in TAVR, Real-World Registry Shows

Jun 12, 2023 by
Bailey Salimes, CRTonline.org

Patients with intermediate and high surgical risk who underwent transcatheter aortic valve replacement (TAVR) with balloon-expandable valves had higher rates of measured prosthesis-patient mismatch (PPMM) than PPM predicted (PPMP), and both PPMM and PPMP were reduced when the effective orifice area (EOA) was adjusted to body mass index (BMI), a new study shows.

PFO Closure Shows No Differences in Outcomes Between Patients With and Without Thrombophilia

Jun 12, 2023 by
Nathan Gray, CRTonline.org

Patients with thrombophilia should be considered for inclusion in future clinical trials evaluating patent foramen ovale (PFO) closure outcomes, according to new real-world data that report no significant differences in short- and long-term outcomes between PFO patients with and without thrombophilia.

Malnutrition an Adverse Prognostic Factor in Patients with HF and Severe SMR: COAPT Trial Sub-Study

Jun 09, 2023 by
Bailey Salimes, CRTonline.org

Malnutrition was independently associated with higher 4-year mortality risk in patients with heart failure (HF) and severe secondary mitral regurgitation (SMR) who received medical therapy alone, but not in patients who underwent transcatheter edge-to-edge repair (TEER) plus medical therapy for treatment, a new substudy of the COAPT trial shows.

New Device Designed to Close LAA Shows Promise in Preclinical, Early Clinical Studies

Jun 07, 2023 by
Jason Wermers, CRTonline.org

A new device that aims to close the left atrial appendage (LAA) in a different way from existing commercial devices showed promising preclinical and early clinical results, according to a new report.

Machine Learning Optimizes Care of Aortic Stenosis Patients, Study Suggests

Jun 05, 2023 by
Will Chu, CRTonline.org

Machine learning (ML) could improve the care of patients with valve diseases, as researchers demonstrated its ability to schedule an echocardiographic follow-up in patients with mild-to-moderate aortic stenosis (AS).

COAPT Analysis Suggests TEER’s MR Benefits Not Mediated by Reverse Remodeling

May 29, 2023 by
Nathan Gray, CRTonline.org

A greater decrease in left ventricular (LV) volumes from baseline to 6 months was associated with lower clinical event rates between 6 months and 2 years; however, outcomes were not affected by whether patients received transcatheter edge-to-edge repair (TEER) or the severity of mitral regurgitation (MR), according to a new analysis from the COAPT trial.

Single-Center Study: Treatment of MR in Patients with HF Reduces Frailty

May 24, 2023 by
Bailey Salimes, CRTonline.org

Physical frailty—slowness, exhaustion and inactivity—may be improved in patients with heart failure (HF) by treating mitral regurgitation (MR), though patients in advanced HF may have irreversible negative effects on elements of physical frailty, a new study shows.

Study Highlights Potential Predictors of Coronary Obstruction Risk Post-TAVR

May 22, 2023 by
Will Chu, CRTonline.org

Coronary obstruction (CO) following transcatheter aortic valve replacement (TAVR) is a rare, but often fatal, complication, say researchers, who identify a lack of predisposing factors and challenges in treating the blockage as possible explanations.

Study Finds Graver Prognosis in SMR Patients Undergoing MV Surgery After TEER Failure

May 22, 2023 by
Will Chu, CRTonline.org

A new study concludes that patients with secondary mitral regurgitation (SMR) undergoing mitral valve (MV) surgery for transcatheter edge-to-edge repair (TEER) failure face a poorer prognosis compared with those with primary mitral regurgitation (PMR).

VARC-3-Defined Periprocedural Myocardial Injury Found in About 14% of TAVR Patients, According to Study

May 22, 2023 by
Will Chu, CRTonline.org

A new study has identified the occurrence of periprocedural myocardial injury (PPMI) in approximately 14% of patients undergoing transcatheter aortic valve replacement (TAVR), which negatively impacts early and late survival rates.

HighLife Transseptal MVR Shows Treatment Potential for MR Patients with No Alternative Therapies – Feasibility Study

May 19, 2023 by
Bailey Salimes and Jason Wermers, CRTonline.org

The HighLife transseptal mitral valve replacement (TSMVR) device may be suitable for use in patients who have mitral regurgitation (MR) and no alternative therapy to cardiac surgery or other transcatheter treatment and are not responding to guideline-directed medical therapy (GDMT), a new study shows.

MITRAL Trial Shows MViV, MViR, ViMAC Are Reasonable Treatment Options in High-Risk MR Patients

May 19, 2023 by
Bailey Salimes, CRTonline.org

Heart failure (HF) symptoms and quality of life can be improved by use of the Sapien 3 aortic balloon-expandable transcatheter heart valve (THV) in patients undergoing transcatheter mitral valve-in-valve (MViV), valve-in-ring (MViR) and valve-in-mitral annular calcifications (ViMAC), particularly MViV, a new investigation shows.

Real-World Study: BASILICA Shows Lower 1-Year Mortality, Possibly Reduced Complications vs. Chimney Stenting in Prevention of Coronary Obstruction Post-TAVR

May 19, 2023 by
Bailey Salimes, CRTonline.org

Two valid techniques to prevent coronary obstruction (CO) in high-risk transcatheter aortic valve replacement (TAVR) are chimney stenting and a technique known as BASILICA, but BASILICA may reduce complications that arise from ostial stenting without increasing the risk of stroke if the procedure is performed under cerebral embolic protection, a new study shows.

TRILUMINATE Trial Details Qualify-of-Life Improvements in Severe TR Treated with TriClip vs. Medical Therapy

May 19, 2023 by
Jason Wermers, CRTonline.org

A deeper look into the TRILUMINATE pivotal trial results shows that transcatheter edge-to-edge repair (TEER) for patients with symptomatic, severe tricuspid regurgitation resulted in meaningfully improved quality of life in patients with mostly concomitant, but treated, left-sided valve disease.

Transapical TMVR Improves Clinical Outcomes, Shows Similar Mortality vs. GDMT Alone in Secondary MR – Propensity-Matched Analysis

May 19, 2023 by
Jason Wermers, CRTonline.org

In patients with secondary mitral regurgitation (MR), at 2 years, transcatheter mitral valve replacement (TMVR) with mostly transapically implanted devices was associated with better clinical outcomes and symptomatic improvement and similar mortality in comparison with guideline-directed medical therapy (GDMT) alone, a new analysis shows.

First-Generation Portico THV Shows Comparable 5-Year Results to Commercially Available Valves – PORTICO IDE Trial

May 18, 2023 by
Jason Wermers, CRTonline.org

Five years after undergoing transcatheter aortic valve replacement (TAVR), patients with severe aortic stenosis at high or extreme surgical risk who received the first-generation Portico valve system had comparable rates of all-cause mortality or stroke, excellent and sustained mean gradients and mean valve areas, comparable valve durability, and similar improvements in quality of life when compared to similar patients receiving commercially available valves, new trial results show.

Women Taking Aspirin at Greater Risk of Bleeding Episodes Pre- and Post-TAVR: Post Hoc Analysis

May 08, 2023 by
Will Chu, CRTonline.org

Women are at a greater risk than men of having a major or life-threatening bleeding when receiving aspirin before and after a transcatheter aortic valve replacement (TAVR) is performed, a post hoc analysis concludes.

High Percentage of RV Pacing Linked to Higher Risks in TAVR Patients Receiving Permanent Pacemaker

May 08, 2023 by
Nathan Gray, CRTonline.org

Transcatheter aortic valve replacement (TAVR) patients undergoing permanent pacemaker implantation (PPI) with right ventricular pacing (VP) of above 40% are at increased risk for cardiovascular (CV) death and heart failure (HF) hospitalization compared with patients with under 40% right VP, new registry data show.

Preprocedural CCTA Added to Echo Associated with LAA Closure Success in Short, Long Terms – SWISS-APERO Post Hoc Analysis

May 03, 2023 by
Ilan Merdler, CRTonline.org

The use of preprocedural cardiac computed tomography angiography (CCTA) on top of periprocedural echocardiography is associated with a higher rate of both short- and long-term procedural success in left atrial appendage closure (LAAC) procedures, a new analysis shows.

PASCAL System Contributes to TR Improvements and Higher QOL, Say Researchers

May 01, 2023 by
Will Chu, CRTonline.org

The PASCAL system is a low-risk transcatheter solution, said researchers in a new study that underlines its low complication and high survival rates, culminating in a higher quality of life after 1 year.

Up-Titration of Guideline-Directed Medical Therapy After M-TEER Linked to Reduced Risk of Clinical Events

Apr 24, 2023 by
Nathan Gray, CRTonline.org

Up-titration of guideline-directed medical therapy (GDMT) after transcatheter edge-to-edge mitral valve repair (M-TEER) may be independently associated with a reduced risk of clinical events including mortality and heart failure (HF) hospitalization, according to a new analysis of EuroSMR registry data.

Registry Analysis Questions TAVR-First Strategy for Younger Patients

Apr 24, 2023 by
Nathan Gray, CRTonline.org

The use of transcatheter aortic valve replacement (TAVR) as the first valve strategy “may not be warranted” in patients with life expectancy beyond the TAVR valve and unsuitable anatomy for redo-TAVR, reports a new study.

Surgical Explantation of TAVR is ‘Riskier’ than Redo-TAVR: Registry Data

Apr 24, 2023 by
Nathan Gray, CRTonline.org

Compared with redo-transcatheter aortic valve replacement (TAVR) for transcatheter heart valve (THV) failure, surgical explantation of TAVR is riskier, with earlier reintervention and higher 30-day mortality, but similar mid-term prognosis after landmark analysis, according to a new international registry of patients.

Study Calls for Guideline Revision as LV Volume Thresholds Vary in Older Patients and Women with AR

Apr 10, 2023 by
Will Chu, CRTonline.org

Older patients and women with chronic aortic regurgitation (AR) maintained smaller left ventricular (LV) volumes than younger patients and men, resulting in the development of adverse events (AE) at lower LV volumes, according to new research.

Transcatheter Tricuspid Valve Intervention for Treatment of TR Produces Similar Outcomes in Both Sexes – European Study

Apr 05, 2023 by
Bailey Salimes, CRTonline.org

Both men and women demonstrate similar survival rates after transcatheter tricuspid valve intervention (TTVI), despite having differences in etiology, a new study shows.

Addressing Peridevice Leak in LAAO Requires ‘Holistic Approach’ to Prevention and Treatment, Review States

Mar 27, 2023 by
Nathan Gray, CRTonline.org

Despite recent advances and increasing adoption, certain issues with left atrial appendage occlusion (LAAO) remain, including the frequency of peridevice leak (PDL), which has been shown to confer a higher risk for subsequent ischemic events, warns a new review.

Study Backs Novel Commissural Alignment Technique in TAVR Patients With ACURATE Neo2

Mar 27, 2023 by
Nathan Gray, CRTonline.org

New data from the first large consecutive evaluation of commissural alignment using a novel technique across all patients receiving an ACURATE Neo2 transcatheter aortic valve replacement (TAVR) device show that alignment was achieved in nearly all patients without safety concerns or impact to procedure duration.

Leaflet Morphology Not a Factor in Cardioband Success or Efficacy, Study Concludes

Mar 27, 2023 by
Will Chu, CRTonline.org

Leaflet morphology does not affect the efficacy and safety of transcatheter direct annuloplasty using Cardioband that reduces tricuspid regurgitation (TR) grade and heart failure symptoms, a new study finds.

Moderate Aortic Stenosis Linked to Higher Hospitalization, Death Rates in HFrEF Patients, Study Finds

Mar 27, 2023 by
Will Chu, CRTonline.org

In patients with heart failure with reduced ejection fraction (HFrEF), moderate aortic stenosis (AS) is linked to higher rates of heart failure (HF) hospitalization and mortality when compared to those without AS and even severe AS, new research concludes.

Up-Titrating GDMT after M-TEER for Secondary MR in HFrEF Patients Associated with Better Outcomes – European Registry Analysis

Mar 22, 2023 by
Jason Wermers, CRTonline.org

Among patients with heart failure with reduced ejection fraction (HFrEF) undergoing mitral valve transcatheter edge-to-edge repair (M-TEER) for treatment of secondary mitral regurgitation (SMR), increasing the dosage of guideline-directed medical therapy (GDMT) after M-TEER was associated with marked improvement in MR, survival and freedom from HF hospitalization (HFH), a new registry analysis shows.

Third-Generation TEER System Provides Substantial MR Reduction at 1 Year: EXPAND Study

Mar 13, 2023 by
Sukhdeep Bhogal, CRTonline.org

The third-generation MitraClip NTR/XTR transcatheter edge-to-edge repair (TEER) system resulted in significant reduction in mitral regurgitation (MR) in contemporary real-world practice, compared to earlier randomized controlled trials, according to new registry results.

ViV on Degenerated Internally Stented Bioprosthetic Valves Is Safe, Retrospective Study Shows

Mar 13, 2023 by
Jason Wermers, CRTonline.org

Despite a higher risk of coronary obstruction with degenerated internally stented bioprosthetic valves, performing valve-in-valve (ViV) procedures in patients with these valves shows a similar rate of 3-year survival to ViV procedures in other degenerated bioprosthetic valves, a single-center retrospective study suggests.

Valve Underexpansion in ViV TAVR Produces Worse Hemodynamic Outcomes – Single-Center Study

Mar 13, 2023 by
Bailey Salimes, CRTonline.org

Valve-in-valve (ViV) transcatheter aortic valve replacement (TAVR) often produces results in underexpansion of the functional portion of transcatheter heart valve (THV) prostheses, particularly when these are deeply implanted, which leads to worse hemodynamics, a new study shows.

Intraprocedural Residual MR Predicts 1-Year Mortality after Mitral TEER – MITRA-PRO Registry

Mar 13, 2023 by
Pavan Reddy, CRTonline.org

Among all comers receiving mitral transcatheter edge-to-edge repair (TEER), intraprocedural residual mitral regurgitation (MR) with MitraScore ≥4 was associated with increased rate of mortality at 1 year, a multicenter registry study shows.

Mitral TEER for Degenerative MR Safe, Highly Successful in Older Patients – TVT Registry Analysis

Mar 05, 2023 by
Jason Wermers, CRTonline.org

The safety profile of transcatheter edge-to-edge repair (TEER) of the mitral valve for degenerative mitral regurgitation (MR) was excellent, with a high rate of successful TEER that increased over 8 years in an older patient population, according to an analysis of the real-world Society of Thoracic Surgeons (STS)/American College of Cardiology (ACC) Transcatheter Valve Therapy (TVT) Registry.

Evolut Low-Risk Study Shows Better Long-Term Outcomes at 3 Years Post-TAVR versus SAVR

Mar 05, 2023 by
Bailey Salimes, CRTonline.org

After 3 years, patients who underwent transcatheter aortic valve replacement (TAVR) demonstrated greater benefit than those who underwent surgery with respect to all-cause mortality or disabling stroke, a new study shows.

Mitral TEER with MitraClip Still Shows Lower HF Hospitalization, All-Cause Death vs. Medical Therapy Alone at 5 Years in Functional MR – COAPT

Mar 05, 2023 by
Jason Wermers, CRTonline.org

Transcatheter edge-to-edge repair (TEER) of the mitral valve plus maximally tolerated guideline-directed medical therapy (GDMT) in patients with severe functional mitral regurgitation (MR) continued to show a significantly lower rate of heart failure hospitalization or all-cause mortality than GDMT alone through 5-year follow-up, new results from the COAPT trial show.

Minimally Invasive MV Repair Shows Similar Safety, Efficacy to Sternotomy – UK Mini Mitral Trial

Mar 05, 2023 by
Bailey Salimes, CRTonline.org

Minimally invasive mitral valve repair (mini-MVr) is comparable to sternotomy in terms of safety and efficacy for the treatment of degenerative mitral regurgitation (DMR), though initial recovery is better in patients who undergo Mini MVR, a new analysis shows.

TRILUMINATE: TriClip Superior to Medical Therapy Alone at 1 Year in Severe Tricuspid Regurgitation

Mar 04, 2023 by
Jason Wermers, CRTonline.org

Transcatheter edge-to-edge repair (TEER) of the tricuspid valve with the TriClip device was superior to medical therapy alone at 1 year as treatment for severe or worse tricuspid regurgitation (TR), with significant improvements in quality of life for those undergoing the procedure, new randomized trial results show.

Amulet Shows Fewer Severe Leak Predictors in Larger LAA Anatomies, More Procedural Predictors vs. Watchman – Amulet IDE Analysis

Feb 28, 2023 by
Jason Wermers, CRTonline.org

Larger left atrial appendage (LAA) anatomy is a predictor of severe peri-device leak (PDL) in the Watchman device, but not with the Amulet device, while the Amulet, which is a newer device, had more procedure-related predictors of severe PDL, a new analysis shows.

PCI Post-TAVI Shows Better 2-Year Outcomes Than Concurrent or Pre-TAVI Procedures

Feb 28, 2023 by
Bailey Salimes, CRTonline.org

At 2 years, percutaneous coronary intervention (PCI) performed after transcatheter aortic valve implantation (TAVI) showed significantly lower rates of all-cause death and a composite endpoint compared with other PCI timings relative to TAVI, a new analysis shows.

TELLTALE Electrosurgery Guidewire System Wins CRT 2023 Best Innovation Award

Feb 27, 2023 by
Jason Wermers, CRTonline.org

A transcatheter electrosurgery guidewire system that can potentially be used in several procedures won the Best Innovation Award at Cardiovascular Research Technologies (CRT) 2023.

LAAO with Watchman Safe, Effective in Patients with NVAF, ESRD – EPIC06-WATCH HD Study

Feb 27, 2023 by
Jason Wermers, CRTonline.org

Left atrial appendage occlusion (LAAO) with the Watchman device is a safe and effective intervention for patients with non-valvular atrial fibrillation (NVAF) and end-stage renal disease (ESRD) on hemodialysis to prevent both embolic and bleeding events, a new observational study shows.

LAAO Provides Similar Benefits in Elderly, Younger Patients: Pooled Analysis

Feb 27, 2023 by
Bailey Salimes, CRTonline.org

Left atrial appendage occlusion (LAAO) shows similar benefit to both elderly and younger patients, new data shows.

PORTICO NG Substudy Explores Factors Influencing Risk of New Permanent Pacemaker Post-TAVI

Feb 27, 2023 by
Jason Wermers, CRTonline.org

Pre-existing atrioventricular conduction abnormalities, membranous septum length and implant depth influence the risk of new permanent pacemaker implantation (PPI) at 30 days after transcatheter aortic valve implantation (TAVI) with the new Navitor valve, a new study subgroup analysis shows.

WATCHMAN FLX Implantation Safe for Routine Clinical Use – SURPASS Study

Feb 27, 2023 by
Bailey Salimes, CRTonline.org

In patients implanted with the WATCHMAN FLX device, mortality was greater in men, but women had more instances of major bleeding and pericardial effusion that required intervention within 1 year, while overall, the device was safe, a new study shows.

Extent of Cardiac Damage Prior to AVR Impacts Baseline and 1-Year Health Status: PARTNER Trials Post Hoc Analysis

Feb 20, 2023 by
Pavan Reddy, CRTonline.org

Among patients undergoing aortic valve replacement (AVR), the extent of cardiac damage at baseline was associated with lower Kansas City Cardiomyopathy Questionnaire (KCCQ) scores at baseline and at 1 year as well as increased risk of poor outcome (death or poor health status), a post hoc analysis of the PARTNER trials shows.

Cardiology Groups’ Statement Seeks to Define Advanced Training for Interventional Cardiology

Feb 16, 2023 by
Bailey Salimes, CRTonline.org

The American College of Cardiology (ACC), American Heart Association and Society for Cardiovascular Angiography & Interventions (SCAI) emphasized the importance of maintaining and updating standards of care and advancing skills in the practice of interventional cardiology in a new statement.

Emergence of TEER Is Associated with Improved 30-Day, 5-Year Outcomes in Degenerative MR: STS Database Analysis

Feb 06, 2023 by
Sukhdeep Bhogal, CRTonline.org

With the introduction of transcatheter edge-to-edge repair (TEER), the overall surgical mitral valve repair (MVr) case volume for degenerative mitral regurgitation (DMR) has not changed significantly; however, institutions adopting TEER are associated with a reduction in higher-risk surgical operations and improved 30-day and 5-year outcomes, according to a new Society of Thoracic Surgeons (STS) database analysis.

PASCAL IID Registry: PASCAL System Useful Treatment for Degenerative MR with Complex Anatomy

Jan 30, 2023 by
Ilan Merdler, CRTonline.org

The PASCAL system is a useful therapy for degenerative mitral regurgitation (DMR) with complex mitral valve anatomy, according to a new study.

Designation of Comprehensive Stroke Center Is Associated with Increased Stroke Rate After TAVR: Michigan TVT Registry Analysis

Jan 23, 2023 by
Pavan Reddy, CRTonline.org

In an analysis of the Transcatheter Valve Therapy (TVT) Registry of reported stroke in Michigan, hospitals with a designation of Comprehensive Stroke Center (CSC) were found to be associated with a higher 30-day stroke rate after transcatheter aortic valve replacement (TAVR), in comparison with non-CSC institutions.

Cathlas App Provides Video Library for Interventional Cardiologists

Jan 12, 2023 by
Jason Wermers, CRTonline.org

Clinicians studying for the interventional cardiology boards, or experienced interventional cardiologists dealing with rare complications or facing uncommon anatomical anomalies, can now turn to an app to expand their knowledge.

No Antiplatelet Strategy Post-TAVR Showed Similar NACE, Lower Bleeding Rates vs. SAPT or DAPT: OCEAN-TAVI Registry

Jan 09, 2023 by
Sukhdeep Bhogal, CRTonline.org

No antithrombotic therapy was associated with a comparable rate of net adverse clinical events (NACEs) to single-antiplatelet therapy (SAPT) or dual-antiplatelet therapy (DAPT), according to a new OCEAN-TAVI Registry analysis.

ShortCut Device Successfully Splits Failed Bioprosthetic Valve Leaflets in ViV TAVR – First-in-Human Study

Jan 09, 2023 by
Jason Wermers, CRTonline.org

The first dedicated transcatheter leaflet-splitting device demonstrated safety and successfully prevented coronary obstruction after transcatheter aortic valve replacement (TAVR) in a first-in-human trial of patients with failed bioprosthetic valves.

Study: Black Individuals Less Likely to Undergo Minimally Invasive MV Surgery, More Likely to Die or Face Major Complications vs. White Patients

Dec 21, 2022 by
Jason Wermers, CRTonline.org

Non-Hispanic Black patients were less likely to undergo minimally invasive mitral valve surgery (MIMVS) and had a higher risk of mortality or major complications than their non-Hispanic white counterparts, new study data report.

MitraClip or PASCAL Use in Mitral Valve TEER Success Comparable, Study Suggests

Dec 19, 2022 by
Will Chu, CRTonline.org

Mitral valve transcatheter edge-to-edge repair (TEER) using either the MitraClip or PASCAL device was safe, and both devices offered similar technical success and comparable short- and long-term outcomes, according to a new study.

Population-Based Study: New-Onset AF without Structural Heart Disease Increases Risk for Incident TR

Dec 05, 2022 by
Pavan Reddy, CRTonline.org

Among patients without structural heart disease, atrial fibrillation (AF) leads to increased incidence of moderate or greater tricuspid regurgitation (TR), and isolated TR or moderate or greater TR is associated with long-term mortality, according to a population-based study utilizing a record linkage system.

Computational Model Mostly Predicts LAA Closure Device Implantation Characteristics, Small Study Shows

Nov 30, 2022 by
Jason Wermers, CRTonline.org

A computational model predicted the final size of implanted WATCHMAN FLX devices in 72.7% of patients undergoing left atrial appendage closure (LAAC) in a small, single-center, observational study, new results show.

Quality of Life, HF Symptoms Improved at 2-Year Post-TMVR Follow-Up – MITRAL Study

Nov 28, 2022 by
Bailey Salimes, CRTonline.org

The use of balloon-expandable aortic transcatheter heart valves might improve symptoms, quality of life and stable prosthesis function in patients with severe mitral annular calcification (MAC), failed annuloplasty ring and bioprosthetic mitral valve (MV) dysfunction at 2-year follow-up, a new study suggests.

Study Links Higher Maternal and Fetal Cardiac Events with SVD of Left-Sided vs. Right-Sided Bioprosthetic Valves

Nov 14, 2022 by
Will Chu, CRTonline.org

A study has found that in a cohort of pregnant women implanted with bioprosthetic valves (BPV), structural valve dysfunction (SVD) of left-sided BPVs was linked to higher rates of adverse pregnancy outcomes compared to right-sided BPVs.

Botulinum Toxin A Does Not Significantly Reduce Post-Operative AF, Phase 2 NOVA Study Finds

Nov 07, 2022 by
Pavan Reddy, CRTonline.org

Among patients undergoing cardiac surgery, botulinum toxin type A (AGN-151607) did not significantly reduce post-operative atrial fibrillation (POAF) events in the primary analysis of a phase 2 dose-ranging study.

New Study Suggests Psychosocial Risk Factors May Influence AVR Outcomes

Oct 26, 2022 by
Bailey Salimes, CRTonline.org

A new study shows that patients with psychosocial risk factors (PSRFs) have worse short-term outcomes after going through surgical aortic valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR) but that these negative outcomes were more likely post-SAVR.

PROVE-HF: Sacubitril/Valsartan Shows MR Reduction in HFrEF Patients

Oct 02, 2022 by
Jason Wermers, CRTonline.org

The use of sacubitril/valsartan on top of optimal guideline-directed medical therapy (GDMT) in patients with heart failure with reduced ejection fraction (HFrEF) and functional mitral regurgitation (MR) showed improvement in MR severity, according to new results from an observational study.

Intrepid TMVR Shows ‘Encouraging’ Echocardiographic Results in Surviving High-Risk Patients with Severe MR at 3 Years

Sep 18, 2022 by
Jason Wermers, CRTonline.org

BOSTON — Of the surviving high-surgical-risk patients who underwent transapical transcatheter mitral valve replacement (TMVR) to treat severe mitral regurgitation (MR) at 3 years, echocardiographic outcomes showed stable valve function, persistent MR reduction and a significant reduction in left ventricular end-diastolic volume from baseline, new study results show.

PARTNER Trials Analysis: Extent of Cardiac Damage at Baseline Impacts Post-AVR Quality of Life for Aortic Stenosis Patients

Sep 18, 2022 by
Jason Wermers, CRTonline.org

BOSTON — Aortic stenosis patients with greater cardiac damage had less quality-of-life improvement at 1 year after aortic valve replacement (AVR), while those whose cardiac damage lessened in the year after AVR also had greater quality-of-life improvement, a new analysis shows.

Changes to Devices and Procedures Linked to Lower Long-Term TAVR Mortality, Study Finds

Sep 18, 2022 by
Will Chu, CRTonline.org

There is a strong association of changes in device and procedural factors with changes in long-term mortality, likely driven by their association with short-term complications of transcatheter aortic valve replacement (TAVR), a new registry analysis shows.

Analysis: Surgical Explant of THVs After TAVR Brings Higher Risk vs. Redo SAVR

Sep 18, 2022 by
Jason Wermers, CRTonline.org

BOSTON — Surgical explantation of transcatheter heart valves (THVs) after transcatheter aortic valve replacement (TAVR) confers a higher risk of mortality and other clinical outcomes compared with redo surgical aortic valve replacement (SAVR), a new analysis shows.

Fracturing Bioprosthetic THVs Shows Increased Mortality Risk, ‘Modest’ Hemodynamic Benefit, in ViV TAVR – Analysis

Sep 18, 2022 by
Jason Wermers, CRTonline.org

BOSTON — Fracturing balloon-expandable bioprosthetic transcatheter heart valves (THVs) was associated with an early risk of in-hospital mortality, especially when performed before valve-in-valve (ViV) transcatheter aortic valve replacement (TAVR), a new registry analysis shows.

Lower Mortality and Excellent Hemodynamics with Portico Valve FlexNav Delivery and Predecessor: CONFIDENCE Registry

Sep 18, 2022 by
Sukhdeep Bhogal, CRTonline.org

The first-generation Portico delivery system (DS) and second-generation FlexNav DS demonstrated excellent clinical results in high- and extreme-surgical-risk patients, according to the findings from the large, real-world CONFIDENCE Registry.

No Significant 5-Year Mortality Difference Between Surgical and Percutaneous Repair of Post-Infarct VSD: UK Registry

Sep 17, 2022 by
Natalie Morrison, CRTonline.org

The first head-to-head comparison of surgical vs. transcatheter repair of a post-infarct ventricular septal rupture found no significant difference in 5-year cumulative all-cause mortality.

PASCAL Registry Data Show Valve Repair System Is Effective in High-Risk Patients with Complex Anatomy

Sep 17, 2022 by
Nathan Gray, CRTonline.org

Transcatheter edge-to-edge repair (TEER) with the PASCAL valve repair system is both safe and clinically effective in prohibitive-risk patients with degenerative mitral regurgitation (DMR) and complex valve anatomy, according to new 30-day and 6-month follow-up data.

Amulet LAA Occluder Continues to Prove Safe and Effective at 3 Years in Head-to-Head Trial with Watchman

Sep 17, 2022 by
Natalie Morrison, CRTonline.org

The Amulet left atrial appendage (LAA) occluder device continued to demonstrate safety and effectiveness through 3 years in the Amulet IDE trial, study lead Dhanunjaya Lakkireddy, MD, reported Saturday at the Transcatheter Cardiovascular Therapeutics (TCT) 2022 conference in Boston.

EXPAND G4: Newest MitraClip Devices Safe, Effective in Primary and Secondary MR

Sep 17, 2022 by
Jason Wermers, CRTonline.org

BOSTON — Transcatheter edge-to-edge repair (TEER) with the newest-generation MitraClip G4 system demonstrated safety and effectiveness in both primary and secondary mitral regurgitation (MR), according to new study results.

SCOPE I Trial Finds No Clinical Outcome or Failure Differences for ACURATE Neo and SAPIEN 3 Valves at 3 Years

Sep 17, 2022 by
Will Chu, CRTonline.org

Differences in procedural outcomes and performance between the ACURATE neo and SAPIEN 3 bioprosthetic valve devices did not translate into significant differences in clinical outcomes or device failure after 3 years.

MicroCT Shows Promise for Detection of Leaflet Thickening: Data

Sep 17, 2022 by
Nathan Gray, CRTonline.org

High-resolution microCT imaging can provide an accurate detection of hypo-attenuating leaflet thickening (HALT) and is capable of determining leaflet thickening rate when compared to histological analysis, new data reveal.

CLASP IID Trial Results Add a Transcatheter Option for Inoperable DMR, Researchers Say

Sep 17, 2022 by
Natalie Morrison, CRTonline.org

Transcatheter treatment options are expanded for patients with significant symptomatic inoperable degenerative mitral regurgitation (DMR) after the PASCAL system for the first time proved non-inferior to MitraClip in the CLASP IID trial, said the researchers.

TEER Linked to Reduction of MR in Patients Presenting with Cardiogenic Shock, Study Finds

Sep 17, 2022 by
Will Chu, CRTonline.org

Patients with severe mitral regurgitation (MR) and cardiogenic shock (CS) who underwent mitral transcatheter edge-to-edge repair (TEER) achieved successful MR reduction, new study findings suggest.

FRANCE-TAVI Analysis: Self-Expanding Valves Show Superior Hemodynamic Performance vs. Balloon-Expandable Valves at 1 Year

Sep 17, 2022 by
Jason Wermers, CRTonline.org

Self-expanding transcatheter heart valves showed superior hemodynamic performance to that of balloon-expandable valves (BEVs) at 1 year after transcatheter aortic valve replacement (TAVR) in patients with severe aortic stenosis and small aortic annuli, a new registry analysis shows.

CEP Did Not Lower Risk of Stroke in TAVR: PROTECTED TAVR Data

Sep 17, 2022 by
Nathan Gray, CRTonline.org

Use of a cerebral embolic protection (CEP) device did not lead to a lower risk of stroke or mortality in patients undergoing transcatheter aortic valve replacement (TAVR) patients, according to new trial data.

FDA, Abbott Warn of Potential Clip Lock Malfunctions with MitraClip Delivery Systems

Sep 09, 2022 by
Jason Wermers, CRTonline.org

The U.S. Food and Drug Administration (FDA) has sent a letter to health-care providers warning about the potential for clip lock malfunctions on MitraClip Delivery Systems manufactured by Abbott.

MR Etiology Impacts 2-Year Outcomes Despite Procedural Success, Study Shows

Sep 05, 2022 by
Nathan Gray, CRTonline.org

Despite excellent procedural outcomes, patients with atrial functional mitral regurgitation (a-FMR) and ventricular functional mitral regurgitation (v-FMR) had worse clinical outcomes compared with those with degenerative mitral regurgitation (DMR), according to a new analysis of real-world patient data.

LVEF Cutoff Values Should be Raised from 50% to 55-60% in Bicuspid Aortic Valve Disease, Recommends Study

Sep 05, 2022 by
Will Chu, CRTonline.org

The risk of adverse health outcomes increases significantly in patients with bicuspid aortic valve (BAV) disease if left ventricular ejection fraction (LVEF) falls below 60%, according to researchers.

AI Algorithm Shows Promise in Identifying AS Patients at Risk of Dying if Left Untreated – Australian Study

Aug 28, 2022 by
Jason Wermers, CRTonline.org

An artificial intelligence algorithm that uses routine echocardiograms of patients with moderate to severe aortic stenosis showed promise in correctly identifying which patients have a significant risk of dying if left untreated, according to a new Australian study.

Moderate Aortic Stenosis Associated With Significant Mortality Risk: Meta Analysis

Aug 18, 2022 by
Nathan Gray, CRTonline.org

Patients with moderate aortic stenosis (AS) may have a higher mortality risk than those with no or mild AS but a lower risk than patients with severe AS, according to a new meta-analysis.

Female BAV Patients Undergoing TAVR Have Worse In-Hospital Outcomes than Men Despite Fewer Comorbidities – Chinese Study

Aug 16, 2022 by
Natalie Morrison, CRTonline.org

Women with bicuspid aortic valves (BAVs) undergoing transcatheter aortic valve replacement (TAVR) presented with fewer comorbidities, type 1 BAV, lower calcification and smaller aortic roots than men, yet men had better in-hospital outcomes and comparable 1-year survival, according to a new single-center Chinese study

CAD Severity Is Associated with Adverse 5-Year Outcomes in TAVR, Reports Study

Aug 15, 2022 by
Nathan Gray, CRTonline.org

The presence of coronary artery disease (CAD) in patients undergoing transcatheter aortic valve replacement (TAVR) is associated with significantly worse 5-year outcomes. However, angiography-guided percutaneous coronary intervention (PCI) did not improve outcomes, according to new prospective data.

Review Concludes Valvular Interventions Are ‘Promising’ for MAC, but Warns Benefits Are Not Yet Established

Aug 08, 2022 by
Nathan Gray, CRTonline.org

Mitral annular calcification (MAC)-related mitral valve (MV) dysfunction is increasing in prevalence in older populations and is associated with worse outcomes. However, valvular interventions demand careful discussion by a multidisciplinary heart valve team on the basis of dedicated anatomical imaging and patient goals of care, according to the latest JACC Review Topic of the Week.

Review Describes Standardized Approach for MAC Severity Grading and Treatment

Aug 08, 2022 by
Natalie Morrison, CRTonline.org

A standardized approach for grading the severity of mitral annular calcification (MAC) and the evaluation of patients for surgical or transcatheter intervention has been set out in a new state-of-the-art review.

Discordant Moderate AS Is Frequent and Associated with Increased Mortality: Registry Study

Aug 08, 2022 by
Natalie Morrison, CRTonline.org

Discordant grading is seen frequently in moderate aortic stenosis (AS) and is associated with increased mortality, according to researchers on a new international registry study, who pushed for better phenotyping of these patients.

Deep Learning Algorithms Applied to ECG Could Form New Type of Valvular Heart Disease Screening

Aug 01, 2022 by
Natalie Morrison, CRTonline.org

Machine learning analysis of 12-lead electrocardiography (ECG) could provide a new type of valvular heart disease (VHD) screening program, said researchers on a new study that found “deep learning” algorithms could accurately detect aortic stenosis (AS), aortic regurgitation (AR) and mitral regurgitation (MR).

FDA-Accepted Levels of Watchman Peridevice Leak Linked With Greater Long-Term Thromboembolism Risk

Jul 25, 2022 by
Natalie Morrison, CRTonline.org

A post-implantation peridevice leak (PDL) of 5 mm or less after percutaneous left atrial appendage (LAA) closure with the Watchman device is linked with greater risk of thromboembolism over 5 years, a new follow-up study has found.

Genetic Predictors of Aortic Stenosis and Aortic Aneurysm Defined in New UK Biobank Analysis

Jul 25, 2022 by
Natalie Morrison, CRTonline.org

Genetic signatures that could predispose people to aortic stenosis (AS), and which could be most relevant to predicting thoracic aortic aneurysm, have been defined by researchers on a large UK population-based biobank.

Early Clinical Experience with PASCAL Leaflet Repair System Shows 'High' Technical and Procedural Success: Observational Study

Jul 05, 2022 by
Natalie Morrison, CRTonline.org

Early European clinical experience data for the PASCAL and PASCAL Ace leaflet repair systems show high technical success and procedural safety rates, said researchers on a new observational study, with efficient reduction of tricuspid regurgitation (TR) sustained for more than 5 months’ median follow-up

Registry Data: Low Socioeconomic Status Associated with Increased Risk of Bleeding After Aortic Valve Replacement

Jun 20, 2022 by
Nathan Gray, CRTonline.org

There is a strong association between socioeconomic status (SES), bleeding risk and fatal intracranial hemorrhage after aortic valve replacement (AVR), new registry data suggest.

TAVR Outcomes May Be Impacted by Center’s Valve Preference: Registry Data

Jun 20, 2022 by
Nathan Gray, CRTonline.org

Overall preference of balloon-expandable valves (BEVs) or self-expanding valves (SEVs) at a center has a significant effect on transcatheter aortic valve replacement (TAVR) outcomes when stratified to valve type, according to a new analysis of registry data.

Commissural Alignment Could Impact Device Performance and Clinical Outcomes for Balloon-Expandable TAVR Patients – RESOLVE Analysis

Jun 06, 2022 by
Natalie Morrison, CRTonline.org

Commissural alignment may impact device performance and clinical outcomes in patients undergoing balloon-expandable transcatheter aortic valve replacement (TAVR), according to a new RESOLVE study analysis.

No Increased Risk of Mortality or Cerebrovascular Events from Post-TAVR HALT: 3-Year Data

Jun 06, 2022 by
Nathan Gray, CRTonline.org

Early hypoattenuated leaflet thickening (HALT) was not associated with a higher risk for mortality or cerebrovascular events after transcatheter aortic valve replacement (TAVR), but may be associated with symptomatic hemodynamic valve deterioration, 3-year follow-up data suggest.

Harmony TPV Safe, Effective at 1 Year in Treating Severe PR – Pooled Analysis

May 19, 2022 by
Sukhdeep Bhogal, CRTonline.org

The largest cohort to date of patients with congenital heart disease and severe pulmonary regurgitation (PR) who received the Harmony transcatheter pulmonary valve demonstrated favorable clinical and hemodynamic outcomes at 1 year.

Evolut PRO Shows Consistent Favorable Outcomes at 3 Years Post-TAVR – FORWARD PRO Study

May 19, 2022 by
Jason Wermers, CRTonline.org

Transcatheter aortic valve replacement (TAVR) with the Evolut PRO valve demonstrated consistent favorable clinical and hemodynamic outcomes through 3 years post-implant, according to data from the FORWARD PRO post-market study.

Cardioband Tricuspid Repair System Significantly Cut TR at 1 Year in Ongoing EFS

May 19, 2022 by
Natalie Morrison, CRTonline.org

Tricuspid repair with the Cardioband valve reconstruction system resulted in a significant and sustained decrease in tricuspid regurgitation (TR), with all 37 patients improving by at least one grade at 1 year in the ongoing U.S. Cardioband TR early feasibility study (EFS).

Early 30-Day Real-World Next-Generation TriClip Data Suggest Improved TR Reduction: bRIGHT Study

May 19, 2022 by
Natalie Morrison, CRTonline.org

The early TriClip G4 experience at 30 days in the ongoing real-world European bRIGHT study suggests improved tricuspid regurgitation (TR) reduction versus the earlier-generation TriClip device, “despite worse TR severity at baseline.”

Bridge-to-Transplant Strategy Shows Promise for Advanced HF Patients with Limited Access to Transplantation: 2-Year MitraBridge Data

May 19, 2022 by
Nathan Gray, CRTonline.org

Using MitraClip as a “bridge-to-transplant” strategy in patients with mitral regurgitation (MR) secondary to advanced heart failure (HF) and limited access to heart transplant (HTx) allowed clinical and hemodynamic stabilization resulting in good clinical outcomes, according to new 2-year data from the MitraBridge study.

30-Day Follow-Up Reports Favorable Outcomes for Transcatheter Tricuspid Valve Repair with PASCAL Ace System

May 19, 2022 by
Nathan Gray, CRTonline.org

Use of the PASCAL Ace transcatheter tricuspid valve repair system in high-risk patients with severe tricuspid regurgitation (TR) is safe and effective, with low adverse events and significant clinical benefits, according to data from the TriCLASP study.

JenaValve Trilogy Demonstrates Safety, Effectiveness in Treatment of Aortic Regurgitation – German Registry

May 18, 2022 by
Jason Wermers, CRTonline.org

Transfemoral transcatheter aortic valve replacement (TAVR) with the JenaValve Trilogy transcatheter heart valve system is safe and effective for the treatment of severe aortic regurgitation, according to the first real-world data on this valve.

Italian Registry: TAVR with ACURATE neo2 Shows Less Paravalvular Leak than Original neo THV

May 18, 2022 by
Amer Aladin and Jason Wermers, CRTonline.org

Transcatheter aortic valve replacement (TAVR) with the second-generation ACURATE neo2 transcatheter heart valve (THV) showed a threefold reduction of greater-than-mild paravalvular leak and comparable technical success in comparison with the first-generation ACURATE neo, according to new registry results

LYTEN: ViV TAVR for Failed Small Surgical Valves Shows Low Rates of Complications, 30-Day Adverse Events

May 18, 2022 by
Jason Wermers, CRTonline.org

In patients with small failed surgical bioprostheses, valve-in-valve (ViV) transcatheter aortic valve replacement (TAVR) was associated with “extremely low” rates of periprocedural complications and 30-day adverse events regardless of the type of transcatheter heart valve used, according to a small randomized controlled trial.

Optimize PRO: TAVR with Self-Expanding THV Using Cusp Overlap, Optimized Care Pathway Leads to Good Outcomes

May 17, 2022 by
Jason Wermers, CRTonline.org

Use of the cusp overlap technique with an optimized care pathway provides excellent outcomes, a low rate of pacemaker implantation, next-day discharge and low rates of residual aortic regurgitation in aortic stenosis patients undergoing transfemoral transcatheter aortic valve replacement (TAVR) with a self-expanding valve, according to new study results.

Swedish Registry Study: Patient-Specific Implant Technique Optimizes Commissural Alignment

May 17, 2022 by
Sukhdeep Bhogal, CRTonline.org

The first large, consecutive evaluation of commissural alignment using a dedicated patient-specific implant technique found it safe and effectively achievable in a majority of patients, with minimal impact on procedural duration.

Low Event Rate, Excellent Hemodynamics with Navitor THV in High-, Extreme-Risk Cohort at 1 Year: PORTICO NG Study

May 17, 2022 by
Sukhdeep Bhogal, CRTonline.org

At 1 year, the Navitor transcatheter heart valve (THV) demonstrated a low adverse event rate and excellent hemodynamics in high- and extreme-surgical-risk patients, according to data from the PORTICO NG study presented Tuesday.

German Registry: JenaValve Trilogy THV Safe, Effective in Treatment of Aortic Stenosis

May 17, 2022 by
Jason Wermers, CRTonline.org

Treatment of aortic stenosis with the JenaValve Trilogy transcatheter heart valve (THV) is safe and effective, according to the first results of commercial implants presented Tuesday at EuroPCR 2022 in Paris.

Dilated Aortic Root Associated with Higher Rates of Aortic Dissection at a Smaller Diameter: IRAD Registry

May 09, 2022 by
Sukhdeep Bhogal, CRTonline.org

Patients with modest dilation in the aortic root (AR) had acute type A aortic dissections (ATAD) at a significantly smaller diameter compared to patients with modestly dilated ascending aorta (AA), according to registry data

CMR May Help Assess Risk for Coronary Artery Compression Prior to TPVi

May 02, 2022 by
Nathan Gray, CRTonline.org

Cardiac magnetic resonance (CMR) can be a “useful tool” in assessing risk for coronary artery (CA) compression in patients undergoing transcatheter pulmonary valve implantation (TPVi) for treatment of dysfunctional RV-PA conduits, according to a new multi-center retrospective analysis.

Aspirin-Free Anticoagulant Regimens Post-LAAO with Watchman Carry Less Risk – Large-Scale Registry

May 02, 2022 by
Natalie Morrison, CRTonline.org

Patients undergoing left atrial appendage occlusion (LAAO) with the Watchman device had lower risk of adverse outcomes when discharged on warfarin or direct oral anticoagulant (DOAC) without concomitant aspirin – a step away from the U.S. approved regimen.

Real-World Watchman LAAO Patients at Higher Risk of Death vs. Pivotal Trials’ Populations – Registry Study

May 02, 2022 by
Natalie Morrison, CRTonline.org

Atrial fibrillation (AF) patients in real-world clinical practice who underwent left atrial appendage occlusion (LAAO) with the Watchman device were at higher risk of dying than patients in the two pivotal trials used for its U.S. Food and Drug Administration (FDA) approval.

Elevated Mitral Pressure Gradient Associated with 5-Year Adverse Outcome in Degenerative MR Patients

May 02, 2022 by
Nathan Gray, CRTonline.org

Elevated postprocedural mitral valve pressure gradient (MPG) is an independent predictor of adverse clinical and functional outcomes in patients with degenerative mitral regurgitation (DMR) but not in those with functional mitral regurgitation (FMR), a new long-term outcomes study reports.

FDA Announces Class I Recall of Medtronic’s Harmony Catheter

Apr 27, 2022 by
CRTonline.org

Medtronic’s announced recall of the Harmony delivery catheter for its Harmony Transcatheter Pulmonary Valve (TPV) System has been identified as a Class I recall, the most serious type, according to the U.S. Food and Drug Administration (FDA).

Pooled RCT Data Show Lower 5-Year Valve Deterioration in TAVR vs. SAVR Patients

Apr 04, 2022 by
Jason Wermers, CRTonline.org

Patients who underwent transcatheter aortic valve replacement (TAVR) with a supra-annular self-expanding transcatheter heart valve (THV) showed significantly less structural valve deterioration (SVD) after 5 years than their counterparts who underwent surgical aortic valve replacement (SAVR), a new analysis of two randomized trials shows.

1-Year Data Show Promise for Edge-to-Edge Repair for Tricuspid Regurgitation

Apr 04, 2022 by
Nathan Gray, CRTonline.org

The PASCAL transcatheter valve repair system showed a high survival rate, with significant and sustained tricuspid regurgitation (TR) reduction and clinical, functional and quality-of-life improvements, 1-year follow-up data show.

Residual Peri-Device Leaks Tied to Higher Bleeding, Thromboembolic Risk Post-LAAO – Registry Analysis

Apr 03, 2022 by
Jason Wermers, CRTonline.org

Residual peri-device leaks of any size after left atrial appendage occlusion (LAAO) were associated with modestly higher risk of thromboembolic and bleeding events, according to new registry data.

Monitoring New-Onset AF Immediately Post-TAVR Could Be Necessary Strategy: Large-Scale Meta-Analysis

Mar 21, 2022 by
Natalie Morrison, CRTonline.org

Monitoring for new-onset atrial fibrillation (NOAF) should be considered as a strategy after transcatheter aortic valve replacement (TAVR) as a common and risky complication, though whether it is a causal factor or a marker of “sicker patients” remains unclear, according to a new meta-analysis.

Could TAVR Become an Outpatient Procedure for Low-Risk Patients Following the COVID-19 Pandemic?

Mar 21, 2022 by
Natalie Morrison, CRTonline.org

Transcatheter aortic valve replacement (TAVR) could feasibly become an outpatient procedure for some low-risk patients, according to the authors of the observational multicenter PROTECT TAVR study, who found that same-day discharge (SDD) was safe for 124 highly selected individuals during the COVID-19 pandemic.

2 Post Hoc Matched Analyses Show Similar Outcomes for Tricuspid, Bicuspid Valves 1 Year Post-TAVR

Mar 07, 2022 by
Natalie Morrison, CRTonline.org

Two new 1-year post hoc propensity-matched analyses have found that, in highly selected low-risk patients with bicuspid aortic stenosis (AS), transcatheter aortic valve replacement (TAVR) demonstrated similar outcomes to matched cohorts with tricuspid AS.

Early Trial Data Suggest Edwards Lifesciences’ EVOQUE System Is Safe and Effective in TTVR

Mar 07, 2022 by
Nathan Gray, CRTonline.org

Data from two separate studies suggest the transfemoral EVOQUE system for transcatheter tricuspid valve replacement (TTVR) has acceptable safety and durable efficacy at both 30-day and 1-year follow-up.

CT Study: BASILICA Procedure Appears to Improve Safety in TAVR Patients at High Risk of Coronary Obstruction

Mar 07, 2022 by
Natalie Morrison, CRTonline.org

Improvements to risk assessment of coronary obstruction after transcatheter aortic valve replacement (TAVR) could be made by adopting a “multiparametric” approach, said the researchers of a new 28-patient study of periprocedural computed tomography (CT) scans during BASILICA procedures.

TAVR Outcomes Comparable Between Men, Women in Gulf Region

Mar 01, 2022 by
Nathan Gray, CRTonline.org

Women undergoing transcatheter aortic valve replacement (TAVR) in the Gulf region had comparable outcomes and attributes to men in the Gulf TAVR registry, according to new WIN GULF TAVR registry data.

Transcaval-Access TAVR Appears to Be ‘Attractive’ Alternative to Transfemoral Approach: TVT Registry Analysis

Feb 28, 2022 by
Jason Wermers, CRTonline.org

Among experienced transcatheter aortic valve replacement (TAVR) operators, contemporary transcaval access resulted in a lower risk of stroke and similar bleeding complications in comparison with transaxillary access, although both of these alternative approaches showed increased complications compared to transfemoral access, according to a new analysis of the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy (TVT) Registry.

LAA Closure with WATCHMAN FLX Carries Low 45-Day Event Rates: Wide-Scale Real-World Data

Feb 28, 2022 by
Natalie Morrison, CRTonline.org

The largest study of WATCHMAN FLX patients to date found that left atrial appendage (LAA) closure with the device was associated with low 45-day adverse event rates and peri-device leaks.

TAVR Still Safe, Effective in Low-Risk Patients at 4 Years – LRT Trial Results

Feb 28, 2022 by
Jason Wermers, CRTonline.org

Transcatheter aortic valve replacement (TAVR) continued to be safe in patients with symptomatic, severe aortic stenosis who are at low surgical risk 4 years after the procedure, new trial results show

First-in-Man Data Back Novel Transcatheter Mitral Cerclage Annuloplasty in Persistent or Recurrent MR

Feb 28, 2022 by
Nathan Gray, CRTonline.org

A novel technique and device developed to treat functional mitral valve regurgitation called transcatheter mitral valve cerclage annuloplasty – known as cerclage – shows “significant and sustained” improvements in mitral regurgitation (MR) and heart failure quality of life assessments, trial data suggest.

Transfemoral Mitral Valve Repair System Wins CRT 2022 Best Innovation Competition

Feb 28, 2022 by
Jason Wermers, CRTonline.org

A device designed for transfemoral transcatheter mitral valve repair won the CRT Best Innovation Competition on Monday afternoon.

AI Could Help Solve Echocardiographic Underestimation of PH Severity in Severe TR Patients: German Study

Feb 21, 2022 by
Natalie Morrison, CRTonline.org

Echocardiography “systematically underestimates” pulmonary hypertension (PH) severity in those who also have severe tricuspid regurgitation, but an “extreme gradient algorithm” used in a new study could plug knowledge gaps.

Low TAV-in-TAV Implant Depth Could Help Facilitate Future Coronary Access: In Vitro Evolut Study

Feb 21, 2022 by
Natalie Morrison, CRTonline.org

A low implant depth for balloon-expandable Sapien 3 valves in failed self-expanding Evolut valves could help facilitate future coronary access, new in vitro results suggest.

Ross Procedure Long-Term Survival in Young Adults Comparable with General Population: 17-Year Analysis

Feb 21, 2022 by
Natalie Morrison, CRTonline.org

The “Ross procedure” could mean better long-term survival and fewer complications than prosthetic valves for young adults undergoing aortic valve surgery, according to new 17-year data analyses.

Study Uncovers Complications Associated with MitraClip Failure

Feb 21, 2022 by
Nathan Gray, CRTonline.org

MitraClip failure secondary to loss of leaflet insertion (LLI) or single leaflet detachment (SLD) is not a rare phenomenon and may occur during and beyond hospitalization, according to a new analysis of registry data.

Study Shows RV-PA Coupling Ratio Is Independent Predictor of Short-Term Mortality in TTVR

Jan 31, 2022 by
Giorgio A. Medranda, CRTonline.org

The right ventricular (RV) to pulmonary artery (PA) coupling ratio is an independent predictor of short-term all-cause mortality in patients with severe tricuspid regurgitation (TR) who undergo transcatheter tricuspid valve replacement or repair (TTVR), providing additional prognostic value, according to a new analysis.

VARC-3 Technical Failure Leads to Higher Mortality, Stroke Risk 1 Year Post-TAVR, Swiss Registry Shows

Jan 26, 2022 by
Sukhdeep Bhogal, CRTonline.org

Failure to achieve technical successful transcatheter aortic valve replacement according to the Valve Academic Research Consortium (VARC)-3 definition was associated with a twofold increased risk of the composite endpoint of cardiovascular death and stroke at 1 year after the procedure, according to a new analysis of the Bern TAVR Registry.

2 New Studies Offer Insights into Emerging Field of TAVR Commissural Alignment

Jan 17, 2022 by
Sukhdeep Bhogal, CRTonline.org

Despite commissural alignment, up to one third of patients undergoing transcatheter aortic valve replacement (TAVR) would have risk for coronary overlap (CO); however, optimized coronary alignment decreases the risk of CO by sixfold, according to a study released Monday. Another new study reported that using the right or left cusp overlap view to achieve commissural alignment is also an effective approach to implant one of transcatheter heart valve (THV) commissures in the near center between both coronary ostia in most tricuspid aortic valves (TAV) and type 1 bicuspid aortic valves (BAV).

A Novel Patient-Centered Metric May Improve Risk Stratification in TAVR, Study Suggests

Jan 10, 2022 by
Giorgio A. Medranda, CRTonline.org

Home time is associated with risk-adjusted readmission and mortality rate, representing a novel patient-centered metric that might complement currently used metrics in transcatheter aortic valve replacement (TAVR).

Hydra CE: 1-Year Data Show Favorable Outcomes for Novel Repositionable Hydra THV

Jan 03, 2022 by
Nathan Gray, CRTonline.org

Transcatheter aortic valve replacement (TAVR) with the novel repositionable, self-expanding Hydra transcatheter heart valve (THV) device has “favorable” outcomes in terms of efficacy and complication rates at 1 year, trial data suggest.

Transcatheter Pulmonary Valve Replacement Risk Comparable to Surgical Valve Replacement: Registry

Jan 03, 2022 by
Natalie Morrison, CRTonline.org

Post-transcatheter pulmonary valve (TPV) replacement (TPVR) risk of death and repeated intervention is comparable to that of surgical pulmonary valve replacement patients, according to an international TVPR procedures registry.

Canadian Study: Continuous Monitoring May Aid Diagnosis of Post-TAVR Conduction Abnormalities

Dec 20, 2021 by
Nathan Gray, CRTonline.org

High-degree atrioventricular block (HAVB) and complete heart block (CHB) are rare in patients without electrocardiographic (ECG) changes after transcatheter aortic valve replacement (TAVR); however, patients with baseline right bundle branch block (RBBB) and new-onset conduction disturbances may have increased risk, new data suggest.

Continuous Monitoring Study Reveals “Significant Predictors” of Post-TAVR Delayed Total Atrioventricular Block

Dec 20, 2021 by
Nathan Gray, CRTonline.org

The occurrence of post-transcatheter aortic valve replacement (TAVR) delayed total atrioventricular block (DT-AVB) can be predicted by an intraprocedural increase of the HV interval and by an increase of the PQ interval between baseline and day 2 after the procedure, reports a new trial of implantable loop recorders (ILRs) for continuous electrocardiographic monitoring.

TAVR Patients Frequently Develop Subclinical Leaflet Thrombosis, Risking Ischemic Events

Dec 20, 2021 by
Natalie Morrison, CRTonline.org

Subclinical leaflet thrombosis (SLT) is a “frequent phenomenon” of biological prostheses used in transcatheter aortic valve replacement (TAVR), which, left untreated, raises the risk of unfavorable clinical outcomes such as cerebral ischemic events, according to a new meta-analysis of more than 11,000 patients.

Coandă Effect and Flail Leaflet May Not Be Associated With Severe MR: Study

Dec 13, 2021 by
Nathan Gray, CRTonline.org

While a flail leaflet and Coandă effect that are visible on echocardiography are associated with higher regurgitant volumes and fractions, they are frequently not associated with severe mitral regurgitation (MR) as assessed by cardiac magnetic resonance (CMR), new study data suggest.

SMR Patients Meeting COAPT Criteria Show Better Survival vs. Those Not Meeting Criteria – European Registry Analysis

Dec 06, 2021 by
Amer Aladin, CRTonline.org

Patients with secondary mitral regurgitation (SMR) who met COAPT trial enrollment criteria showed improved survival after mitral valve transcatheter edge-to-edge repair (M-TEER) compared to patients who did not meet these criteria, according to a new retrospective analysis.

Transcatheter Tricuspid Valve Repair Provides Excellent Short-Term Improvements in Quality of Life, Study Reports

Dec 06, 2021 by
Giorgio A. Medranda, CRTonline.org

Edge-to-edge transcatheter tricuspid valve repair (TTVr) using the MitraClip NTR/XTR, TriClip, or Pascal devices provides significant improvements in quality of life for patients with significant tricuspid regurgitation (TR), according to a new study.

Analysis Shows Surge of Overall AVR in Older Adults in the US Since Inception of TAVR

Nov 22, 2021 by
Sukhdeep Bhogal, CRTonline.org

The number of older adults undergoing aortic valve replacement (AVR) has increased by almost 60%, while the rates of mortality, readmission and non-home discharge rates decreased, since the advent of transcatheter aortic valve replacement (TAVR), according to a new analysis of fee-for-service (FFS) Medicare beneficiaries.

Long-Term Data Back SAVR in Younger and Low-Risk Patients

Nov 22, 2021 by
Nathan Gray, CRTonline.org

Long-term registry data show that 85% of surgical aortic valve replacement (SAVR) patients receiving bioprostheses have low surgical risk, with “substantial” survival – especially in younger, low-risk patients.

Decisions Not to Intervene in Aortic Stenosis Fall in Europe

Nov 22, 2021 by
Natalie Morrison, CRTonline.org

One in 5 cases of severe symptomatic aortic stenosis (AS) in the European EORP VHD II survey received no intervention in 2017 despite meeting the European Class I recommendation to intervene.

Posterior Left Pericardiotomy ‘Highly Effective’ at POAF Reduction Post-Cardiac Surgery: PALACS Trial

Nov 14, 2021 by
Natalie Morrison, CRTonline.org

Posterior left pericardiotomy is “highly effective” at reducing postoperative atrial fibrillation (POAF) after cardiac surgery, according to the PALACS trial.

Optimal Treatment Strategy for Moderate TR in Mitral Valve Surgery Patients Still Uncertain; CTCR-MVS Highlights ‘Trade-Offs’

Nov 13, 2021 by
Natalie Morrison, CRTonline.org

The optimal treatment strategy for patients with moderate tricuspid regurgitation (TR) present at the time of surgery to treat primary mitral regurgitation (MR) remains unclear, with “trade-offs” between longer, and therefore riskier, surgery time and potential, but still uncertain, long-term benefit.

AVATAR Trial: Early SAVR Tops ‘Watchful Waiting’ in Asymptomatic Severe AS with Normal LV Function

Nov 13, 2021 by
Jason Wermers, CRTonline.org

Early surgical aortic valve replacement (SAVR) was associated with a lower composite rate of adverse events in comparison with a more conservative treatment strategy for patients with severe, mainly degenerative aortic stenosis (AS) and normal left ventricular (LV) function, according to new trial results.

Transfemoral TMVR Feasibility Study Shows ‘Excellent’ Device Function, No 30-Day Mortality in High-Surgical-Risk MR

Nov 06, 2021 by
Natalie Morrison, CRTonline.org

An early U.S. feasibility study for transfemoral delivery of the Intrepid self-expanding bioprosthetic valve for transcatheter mitral valve replacement (TMVR) showed “excellent” device function in moderate to severe mitral regurgitation (MR) patients at high surgical risk, with no mortality or stroke at 30 days, according to new study findings.

SWISS-APERO: Amulet LAA Closure Device Not Associated with Lower Patency vs. Watchman 2.5 or FLX

Nov 06, 2021 by
Natalie Morrison, CRTonline.org

Only a minority of left atrial appendages (LAAs) were found to be “entirely sealed” at 45-day cardiac computed tomography angiography (CCTA) scan with either the Amulet or new Watchman FLX LAA closure (LAAC) devices – the two most popular platforms on the market – in the SWISS-APERO trial.

Novel Tricuspid Valve Replacement Device Shows Favorable Outcomes for TR: TRISCEND Trial

Nov 06, 2021 by
Nathan Gray, CRTonline.org

Transfemoral tricuspid valve replacement with the novel EVOQUE system has favorable 30-day and 6-month outcomes in patients with tricuspid regurgitation (TR), new trial data report.

4-Year PRAGUE-17 Follow-Up: Continued Non-Inferior Risk Prevention from LAA Closure vs. NOAC in High-Risk AF

Nov 05, 2021 by
Natalie Morrison, CRTonline.org

Left atrial appendage closure (LAAC) remains non-inferior to non-vitamin K oral anticoagulants (NOACs) at preventing major neurological, cardiovascular or bleeding events in high-risk atrial fibrillation (AF) patients after 4 years, according to the PRAGUE-17 trial.

Amulet Maintains Superior Closure vs. Watchman at 12 Months, Study Shows

Nov 05, 2021 by
Jason Wermers, CRTonline.org

The dual-seal Amplatzer Amulet Left Atrial Appendage Occluder continued to show superior closure at 12 months compared to the Watchman Left Atrial Appendage Closure Device, which uses a single occlusive mechanism, according to new trial data.

SURTAVI: 5 Years On, TAVR Shows Similar Outcomes to SAVR in Intermediate-Risk Patients

Nov 05, 2021 by
Jason Wermers, CRTonline.org

Five years after aortic valve replacement in patients with intermediate surgical mortality risk, transcatheter aortic valve replacement (TAVR) with a self-expanding bioprosthetic valve and surgical aortic valve replacement (SAVR) had a similar composite rate of all-cause mortality or stroke, according to new trial results.

TAVR Cost-Effective vs. SAVR in Newly Approved Low-Risk Patients in US, PARTNER 3 Analysis Shows

Nov 05, 2021 by
Natalie Morrison, CRTonline.org

The total costs associated with transcatheter aortic valve replacement (TAVR) were lower at 2 years than surgical aortic valve replacement (SAVR) in low-risk patients with severe aortic stenosis (AS), despite higher procedural costs, according to a new analysis of U.S. data from the PARTNER 3 trial.

TEER and TMVR Procedures and Favorable Outcomes on the Rise in the US

Oct 25, 2021 by
Natalie Morrison, CRTonline.org

Transcatheter edge-to-edge repair (TEER) and transcatheter mitral valve replacement (TMVR) procedures have grown drastically in the U.S. since 2014, with improving outcomes over time, according to new data from the ongoing real-world Transcatheter Valve Therapy (TVT) Registry.

RV Dysfunction Linked to Higher Rate of 2-Year Adverse Outcomes in Patients with Secondary MR

Oct 18, 2021 by
Nathan Gray, CRTonline.org

Right ventricular (RV) dysfunction, as evidenced by ventricular-arterial uncoupling, is “strongly and independently” associated with 2-year adverse outcomes in patients with heart failure (HF) and secondary mitral regurgitation (SMR), according to a new analysis of trial data.

Transcatheter Mitral Valve Repair Has ‘Significant’ Benefit for 1-Year Hospitalizations

Oct 18, 2021 by
Nathan Gray, CRTonline.org

Transcatheter mitral valve repair (TMVr) has a “significant and sustained” effect in reducing both all-cause and heart failure (HF)-related hospitalizations 1 year after procedure compared with the year prior, analysis of new population data reports.

Isolated Transcatheter Tricuspid Valve Repair Shows Benefits for TR: Meta-Analysis

Oct 18, 2021 by
Nathan Gray, CRTonline.org

Isolated transcatheter tricuspid valve repair (ITTVR) may offer significant benefits for patients with tricuspid regurgitation (TR), according to a new meta-analysis of clinical studies.

Novel Algorithm May Guide Revascularization Practice in Patients with Coexisting AS and CAD

Oct 05, 2021 by
Nathan Gray, CRTonline.org

Decisions regarding coronary revascularization of patients with coexisting aortic stenosis (AS) and coronary artery disease (CAD) should be based on understanding this complex relationship, using appropriate coronary assessment and consensus within a multidisciplinary team, say the authors of a new review.

Sapien TAVR Devices Win Expanded Indication May now be used in intermediate-risk patients

Aug 19, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

Sapien TAVR Devices Win Expanded Indication May now be used in intermediate-risk patients

Double, Triple Antithrombotics No Better in Afib After TAVR More bleeding, no fewer CV events in observational study

Aug 15, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

Double, Triple Antithrombotics No Better in Afib After TAVR More bleeding, no fewer CV events in observational study

Cath Lab Recap: Stellarex Balloon; Rapid LV Pacing for TAVR; Gene-Eluting Stent Interventional cardiology news to note

Aug 11, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

Cath Lab Recap: Stellarex Balloon; Rapid LV Pacing for TAVR; Gene-Eluting Stent Interventional cardiology news to note

TAVR Embolic Protection Device Cuts Brain Injury Risk But no improvement in clinical outcomes found in CLEAN-TAVI trial

Aug 09, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

TAVR Embolic Protection Device Cuts Brain Injury Risk But no improvement in clinical outcomes found in CLEAN-TAVI trial

CKD, New-Onset Afib Predictors of Early Post-TAVR Stroke No impact found for valve type and approach

Aug 08, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

CKD, New-Onset Afib Predictors of Early Post-TAVR Stroke No impact found for valve type and approach

Cath Lab Recap: Steerable RF Catheter; Lotus Valve Recall; Anti-Gravity Stress Testing Interventional cardiology news to note

Aug 04, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

Cath Lab Recap: Steerable RF Catheter; Lotus Valve Recall; Anti-Gravity Stress Testing Interventional cardiology news to note

CoreValve Cleared For Lower-Risk TAVR In Europe Clinicians eye a similar expansion for TAVR in the U.S.

Aug 02, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

CoreValve Cleared For Lower-Risk TAVR In Europe Clinicians eye a similar expansion for TAVR in the U.S.

Aortic Leaks Seen With Cardiac MRI Linked to Outcomes Regurgitant fraction, not volume, linked to longer-term mortality

Aug 01, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

Aortic Leaks Seen With Cardiac MRI Linked to Outcomes Regurgitant fraction, not volume, linked to longer-term mortality

Aortic Leaks Seen With Cardiac MRI Linked to Outcomes Regurgitant fraction, not volume, linked to longer-term mortality

Aug 01, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

Aortic Leaks Seen With Cardiac MRI Linked to Outcomes Regurgitant fraction, not volume, linked to longer-term mortality

Amplatzer LAA Occluder Thombosis Reported Clots observed in 17% of next-gen device implantations

Jul 28, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

Amplatzer LAA Occluder Thombosis Reported Clots observed in 17% of next-gen device implantations

Point-of-Care Test Could Flag TAVR Leaks High predictive value of hemostatic blood test compared with TEE in study

Jul 27, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

Point-of-Care Test Could Flag TAVR Leaks High predictive value of hemostatic blood test compared with TEE in study

AAN Nixes Routine PFO Closure Questions definition of 'routine'

Jul 27, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

AAN Nixes Routine PFO Closure Questions definition of 'routine'

Best Valve-in-Valve Position Differs by TAVR Device Hemodynamic projections suggest difference for Sapien, CoreValve

Jul 14, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

Best Valve-in-Valve Position Differs by TAVR Device Hemodynamic projections suggest difference for Sapien, CoreValve

TAVR: Angle Matters for CoreValve Outcomes Sapien devices not as sensitive to anatomic variation, study suggests

Jul 13, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

TAVR: Angle Matters for CoreValve Outcomes Sapien devices not as sensitive to anatomic variation, study suggests

Sapien 3 Results 'Remarkable' for High-Risk Patients PARTNER II data with latest device "sets the bar very high," interventionalists say

Jul 12, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

Sapien 3 Results 'Remarkable' for High-Risk Patients PARTNER II data with latest device "sets the bar very high," interventionalists say

LAA Interventions No Better Than Long-Term Warfarin Meta-analysis pans evidence for devices, surgery

Jul 12, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

LAA Interventions No Better Than Long-Term Warfarin Meta-analysis pans evidence for devices, surgery

Ventricular Arrhythmia Common After LVAD No mortality association, but study was retrospective and small

Jul 11, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

Ventricular Arrhythmia Common After LVAD No mortality association, but study was retrospective and small

Lipids Predict Durability of New Aortic Valves Study draws link, but whether statins would help remains unknown

Jul 08, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

Lipids Predict Durability of New Aortic Valves Study draws link, but whether statins would help remains unknown

TMVR Shows Promise for Severe MAC Even better outcomes predicted “once dedicated prostheses become available”

Jul 05, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

TMVR Shows Promise for Severe MAC Even better outcomes predicted “once dedicated prostheses become available”

Early Procedural Success Seen With Amplatzer in LAA But evidence base still lagging compared with Watchman data

Jul 05, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

Early Procedural Success Seen With Amplatzer in LAA But evidence base still lagging compared with Watchman data

Cath Lab Recap: Another HeartWare Recall; Did Rod Stewart Break Her Heart? Interventional cardiology news to note

Jul 01, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

Cath Lab Recap: Another HeartWare Recall; Did Rod Stewart Break Her Heart? Interventional cardiology news to note

Bicuspid TAVR Gets a Simpler Classification System Anatomic variations may be tied to short-term outcomes

Jun 29, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

Bicuspid TAVR Gets a Simpler Classification System Anatomic variations may be tied to short-term outcomes

Mitral Valve: Better Survival Surgery With a Twisting, Elastic Heart Pre-procedural LV torsion a prognostic tool?

Jun 27, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

Mitral Valve: Better Survival Surgery With a Twisting, Elastic Heart Pre-procedural LV torsion a prognostic tool?

CTA Can Exclude Vessel Blockage Before Valve Surgery But positive findings in meta-analysis need confirmation

Jun 23, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

CTA Can Exclude Vessel Blockage Before Valve Surgery But positive findings in meta-analysis need confirmation

TVT: Turbulence Not Over for TAVR Durability, thrombosis, endocarditis remain challenges

Jun 22, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

TVT: Turbulence Not Over for TAVR Durability, thrombosis, endocarditis remain challenges

ECG Pattern Linked to Delayed AV Block After TAVR Telemetry could be unnecessary without conduction disorders, study suggests

Jun 21, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

ECG Pattern Linked to Delayed AV Block After TAVR Telemetry could be unnecessary without conduction disorders, study suggests

Amplatzer Duct Occluder: Feasible Bail-Out for MitraClip Transcatheter plug works for residual MR, according to small case series

Jun 20, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

Amplatzer Duct Occluder: Feasible Bail-Out for MitraClip Transcatheter plug works for residual MR, according to small case series

Low-Flow After TAVR Tied to Mortality Challenging to monitor but linked to outcome, PARTNER investigators say

Jun 15, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

Low-Flow After TAVR Tied to Mortality Challenging to monitor but linked to outcome, PARTNER investigators say

Infective Endocarditis After TAVR Often Deadly Two-thirds died in the hospital after infection

Jun 13, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

Infective Endocarditis After TAVR Often Deadly Two-thirds died in the hospital after infection

MitraClip Feasible for Obstructive Thickening of Heart Improved symptoms and cardiac output suggested in small series

Jun 13, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

MitraClip Feasible for Obstructive Thickening of Heart Improved symptoms and cardiac output suggested in small series

SAVR and TAVR on Par for Mortality But longer-term data are sorely needed, meta-analysis cautions

Jun 06, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

SAVR and TAVR on Par for Mortality But longer-term data are sorely needed, meta-analysis cautions

Abnormal Longitudinal Strain May Predict LV Dysfunction LV ejection fraction, mass regression not as telling

Jun 03, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

Abnormal Longitudinal Strain May Predict LV Dysfunction LV ejection fraction, mass regression not as telling

Consider RF Needle for Trans-septal Procedures Faster crossings with no risk to clinical outcomes

May 27, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

Consider RF Needle for Trans-septal Procedures Faster crossings with no risk to clinical outcomes

Pre-Ablation Cardiac MRI Finds Thrombi, Too Combining anatomical mapping and thrombus detection feasible

May 27, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

Pre-Ablation Cardiac MRI Finds Thrombi, Too Combining anatomical mapping and thrombus detection feasible

Cath Lab Recap: CPR Devices Reclassified; Milestone for Amplatzer Interventional cardiology news to note

May 27, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

Cath Lab Recap: CPR Devices Reclassified; Milestone for Amplatzer Interventional cardiology news to note

Prosthetic Valve-Patient Mismatch Riskier With Surgery? Mismatch linked to mortality, except with TAVR, meta-analysis shows

May 26, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

Prosthetic Valve-Patient Mismatch Riskier With Surgery? Mismatch linked to mortality, except with TAVR, meta-analysis shows

Survey: Ask for Palliative Consult for VAD/TAVR Protocols and knowledge around end-of-life issues often lacking

May 26, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

Survey: Ask for Palliative Consult for VAD/TAVR Protocols and knowledge around end-of-life issues often lacking

FDA Panel Favors Amplatzer PFO occlusion device scores green light from advisors

May 24, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

FDA Panel Favors Amplatzer PFO occlusion device scores green light from advisors

No Love for Amplatzer From FDA Reviewers Criticism showered on evidence for the PFO occlude

May 23, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

No Love for Amplatzer From FDA Reviewers Criticism showered on evidence for the PFO occlude

EuroPCR: Watchman Safe in Real World Conditions Inexperienced centers not less safe overall, international registry says

May 18, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

EuroPCR: Watchman Safe in Real World Conditions Inexperienced centers not less safe overall, international registry says

EuroPCR: Percutaneous Mitral Valves Face Stubborn Obstruction Risk Mirroring early TAVR, the learning curve is still steep

May 18, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

EuroPCR: Percutaneous Mitral Valves Face Stubborn Obstruction Risk Mirroring early TAVR, the learning curve is still steep

EuroPCR: Degenerated TAVR Not Uncommon by 10 Years "Significant signal ... sooner than what we see in surgical valves”

May 17, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

EuroPCR: Degenerated TAVR Not Uncommon by 10 Years "Significant signal ... sooner than what we see in surgical valves”

EuroPCR: TAVR, LAA Occlusion, Mitral Valve Implant Studies on Tap Buzzworthy PCI trial results to come

May 16, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

EuroPCR: TAVR, LAA Occlusion, Mitral Valve Implant Studies on Tap Buzzworthy PCI trial results to come

Study: Aortic Valve Gradient Key to TAVR Outcomes LVEF, on the other hand, not so much

May 16, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

Study: Aortic Valve Gradient Key to TAVR Outcomes LVEF, on the other hand, not so much

EuroPCR: TAVR Embolic Deflector May Cut Stroke Risk Fewer, smaller CNS infarctions by some measures in pooled analysis

May 12, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

EuroPCR: TAVR Embolic Deflector May Cut Stroke Risk Fewer, smaller CNS infarctions by some measures in pooled analysis

Warfarin 'Dangerous' After Bioprosthetic Valves? Bleeding risk, no benefit found in SAVR meta-analysis

May 11, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

Warfarin 'Dangerous' After Bioprosthetic Valves? Bleeding risk, no benefit found in SAVR meta-analysis

Sedation Linked to Better TAVR Outcomes Early death, stroke rate lower than with general anesthesia in registry

May 09, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

Sedation Linked to Better TAVR Outcomes Early death, stroke rate lower than with general anesthesia in registry

No Early Sex Differences For TAVR Bravo 3 substudy suggests benefit for women on bivalirudin, though

May 06, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

No Early Sex Differences For TAVR Bravo 3 substudy suggests benefit for women on bivalirudin, though

Women Less Likely to Die After TAVR Distinct baseline and procedural characteristics possibly at play

May 06, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

Women Less Likely to Die After TAVR Distinct baseline and procedural characteristics possibly at play

Low Stroke Rate After LAA Closure With No Anticoagulant Observations much better than expected for patients with contraindication

May 03, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

Low Stroke Rate After LAA Closure With No Anticoagulant Observations much better than expected for patients with contraindication

A Better Way to Judge Regurgitation After TAVR But is novel index the 'golden formula'?

Apr 28, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

A Better Way to Judge Regurgitation After TAVR But is novel index the 'golden formula'?

Study: Too Many Centers Doing Too Few Septal Myectomies "The low-volume safety data are unacceptable"

Apr 27, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

Study: Too Many Centers Doing Too Few Septal Myectomies "The low-volume safety data are unacceptable"

CMS Proposes TAVR Payment Cuts Other CV procedures to gain slightly in fiscal year starting in October

Apr 25, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

CMS Proposes TAVR Payment Cuts Other CV procedures to gain slightly in fiscal year starting in October

GI Bleeding Linked to Dysfunctional Prosthetic Valves Catch-22 for valve repair in patients with high bleeding risk

Apr 07, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

GI Bleeding Linked to Dysfunctional Prosthetic Valves Catch-22 for valve repair in patients with high bleeding risk

Embolism Halts Next-Gen Watchman in Europe Cause still unknown, not expected to affect device sold in U.S.

Apr 04, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

Embolism Halts Next-Gen Watchman in Europe Cause still unknown, not expected to affect device sold in U.S.

Higher Volume TAVR Centers Safer for Patients In-hospital mortality tied to institutional volume in national registry data

Apr 04, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

Higher Volume TAVR Centers Safer for Patients In-hospital mortality tied to institutional volume in national registry data

SAPIEN 3 Bests Surgery in 'Intermediate Risk' Patients Outcomes better but rates of aortic regurgitation still favor surgery

Apr 04, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

SAPIEN 3 Bests Surgery in 'Intermediate Risk' Patients Outcomes better but rates of aortic regurgitation still favor surgery

Percutaneous Septal Ablation Safe in Younger Patients, Too Study supports extending age range for hypertrophic cardiomyopathy therapy

Mar 10, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

Percutaneous Septal Ablation Safe in Younger Patients, Too Study supports extending age range for hypertrophic cardiomyopathy therapy

3D Printing Aids Tricky LAA Occlusion Simulated anatomy enhanced procedure and planning in case study

Mar 08, 2016 by
Nicole Lou Reporter, MedPage Today/CRTonline.org

3D Printing Aids Tricky LAA Occlusion Simulated anatomy enhanced procedure and planning in case study

Port of Entry in Infective Endocarditis

Feb 07, 2016
Data regarding the port of microbial entry leading to infective endocarditis are scarce. In a study of 318 patients, the skin, oral or dental and the GI route were the three most common routes of entry accounting for 62%, 29%, and 23% of case, respectively. Intravenous drug use, dental infection colonic polys and colorectal adenocarcinoma were among common sources of infection in each category.

Enduring Efficacy of Watchman

Dec 01, 2015 by
Jens Wiebe, MD; Jennifer Franke, MD; Katharina Lehn, MD; Ilona Hofmann, MD; Laura Vaskelyte, MD; Stefan Bertog, MD; Horst Sievert, MD

The Watchman device is an alternative to oral anticoagulation in patients with atrial fibrillation at risk of stroke. Five-year outcomes from a cohort of 102 such patients has demonstrated annual rates of 0.7% for TIAs, 0.7% for stroke, 1.1% for intracranial hemorrhage, and 3.5% for mortality confirming the safety and feasibility of the Watchman device.

The Challenges of Moderate Ischemic MR

Dec 04, 2014 by
Peter K. Smith, M.D., et al.

Ischemic mitral regurgitation (MR) is associated with increased morbidity and mortality. Whether ischemic MR should be repaired at the time of CABG is unknown. One-year data from a randomized study of 301 patients has indicated that the combination of CABG and mitral repair does not lead to improved LV reverse modeling. This approach was also associated with increased adverse events.

TAVI for Bicuspid AV

Apr 01, 2014 by
Darren Mylotte, et al.

The outcome of TAVI in patients with bicuspid AV stenosis is unknown. Analysis of data from 139 patients has indicated the relative safety and efficacy of TAVI in this population, but the incidence of post-implantation AR was high (28.4%). The latter could be reduced by utilization of multislice CT sizing.

Washington Heart Monitor More »
SAPIEN 3 versus Myval transcatheter heart valves for transcatheter aortic valve implantation (COMARE-TAVR 1): a multicentre, randomised, non-inferiority trial.

May 12, 2025 by
Michael Mahmoudi, MD - C Terkelsen, et al.; Lancet 2025; 405:1362-1372

SAPIEN 3 versus Myval transcatheter heart valves for transcatheter aortic valve implantation (COMARE-TAVR 1): a multicentre, randomised, non-inferiority trial.

Dapagliflozin in patients undergoing transcatheter aortic-valve implantation

Apr 28, 2025 by
Michael Mahmoudi, MD - S Raposeiras-Roubin, et al.; NEJM 2025 Online

Dapagliflozin in patients undergoing transcatheter aortic-valve implantation

Routine cerebral embolic protection during transcatheter aortic-valve implantation

Apr 28, 2025 by
Michael Mahmoudi, MD - R Kharbanda, et al.; NEJM 2025 Online

Routine cerebral embolic protection during transcatheter aortic-valve implantation

Cardiovascular Marketplace More »
Structural heart specialist Transmural Systems strengthens board as it prepares for rapid growth

Oct 15, 2024
Structural heart specialist Transmural Systems strengthens board as it prepares for rapid growth

4C Medical's AltaValve System Secures Dual FDA Breakthrough Device Designations, Expediting Patient Access to Advanced Mitral Valve Therapies

May 08, 2024 by
PRNewswire

4C Medical's AltaValve System Secures Dual FDA Breakthrough Device Designations, Expediting Patient Access to Advanced Mitral Valve Therapies

ABBOTT RECEIVES FDA APPROVAL FOR TRICLIP™, FIRST-OF-ITS-KIND DEVICE TO REPAIR LEAKY TRICUSPID HEART VALVE

Apr 02, 2024 by
PRNewswire

ABBOTT RECEIVES FDA APPROVAL FOR TRICLIP™, FIRST-OF-ITS-KIND DEVICE TO REPAIR LEAKY TRICUSPID HEART VALVE

CRT Poll

What is your first line of therapy for restenosis of DES?

Drug Coated Balloon

Another Drug Eluting Stent

47%
Drug Coated Balloon

53%
Another Drug Eluting Stent

Show Results

CRTonline on Facebook

CRTonline on Twitter

Tweets by CRT_meeting

Explore the Site

Stay Connected

CRT Group Foundation is a not for profit corporation dedicated to providing educational services in the field of cardiology through the website, CRTonline.org and the Cardiovascular Research Technologies (CRT) annual symposium. CRT focuses on the advances and changes in the field of cardiovascular medicine. CRT is designed to provide access to the world’s leading clinicians and the latest research in order to improve practice and treatment outcomes for a variety of health care professionals.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details

LVWS and LV Remodeling Characterize Aortic Stenosis and Mitral Regurgitation: Single-Center Study

Severe Aortic Wall Thrombus in TAVR Patients Linked to Thromboembolic Complications, Including Stroke

Breaking News: Edwards Lifesciences to Acquire JenaValve and Endotronix

Controversial SuAVR Procedures Could Have Midterm Advantages, But Longterm Outcomes Are Unclear: State-of-the-Art Review

Complete Revascularization Superior in Reducing All-Cause Mortality, Meta Analysis Finds

CardioTubeMore Videos »

In the News